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 The recently discovered primate brain-specific voltage-gated potassium channel, Kv11.1-3.1, was 
previously identified as a possible therapeutic target for the treatment of schizophrenia. While this 
channel has shown relevance through clinical meta-analyses, drug discovery and basic investigative 
efforts have been hampered due to low and inconsistent evoked currents in cell-based assays. This 
poor activity is hypothesized to result from deficient trafficking due to the lack of an intact channel-
stabilizing Per-Ant-Sim (PAS) domain, as Kv11.1-3.1 is an N-terminally truncated isoform of the 
parent Kv11.1-1A or hERG (human ether-a-go-go related gene). Stemming from hERG’s notoriety as 
a drug discovery anti-target via promiscuous small molecule binding, which includes many 
antipsychotics, Kv11.1-3.1 has also presented itself as a possible contributor to the polypharmacology 
profile of conventional schizophrenia therapy. However, it has not been possible to inquire into these 
hypotheses.  This work sought to create Kv11.1-3.1 drug discovery infrastructure by establishing 
robust, high throughput assays to develop tool compounds and further validate this potential target. 
 Initial studies characterized Kv11.1-3.1 cellular localization and revealed decreased channel 
expression and cell surface trafficking relative to the PAS-domain containing Kv11.1-1A. Using small 
molecule inhibition of proteasome degradation, cellular expression and plasma membrane trafficking 
were rescued. These findings implicate the importance of the unfolded-protein response and 
endoplasmic reticulum associated degradation pathways in the expression and regulation of this 
schizophrenia risk factor. Utilizing the identified rescue phenomenon, electrophysiological and high 
throughput assay platforms were developed. These assays were applied in screening novel compounds 
for structure activity relationships, along with known antipsychotics. This approach afforded a 
synthetic lead molecule, LI-967, which exhibits high potency, drug like properties, and selectivity for 
Kv11.1-3.1 relative to Kv11.1-1A. Additionally, the developed assays have revealed several 
antipsychotics to be Kv11.1-3.1 selective at clinical exposure levels, notably clozapine, suggesting a 
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 Although vague aspects and events of psychosis have been recorded throughout human history, 
ranging from the Old Testament to Shakespeare, schizophrenia as a classified disorder has only 
existed for the last century.1 While some diagnoses were originally referred to as “dementia 
praecox” to describe a heterogeneous set of symptoms, even today, what defines a schizophrenia 
diagnosis is controversial as patients can experience a wide variety of symptoms which are often 
conflated with other mental disorders.1,2 This has led some groups to reconsider schizophrenia as 
a “psychosis spectrum syndrome”, which they cite as more scientifically appropriate 
terminology.3 
 Historically, classical schizophrenia has been defined as the presentation of three distinct classes 
of core symptoms: positive (abnormal experiences such as sensory hallucinations, delusions, 
disordered thoughts and speech, etc.), negative (loss of common behavior such as apathy, 
anhedonia, flattened or blunted affection, alogia, asociality, etc.), and cognitive (deficits in 
working memory, executive function, long-term memory, learning, etc.).2,4-6 Until recently, 
neurological symptoms (catatonia, posturing, mannerism, stereotypy) were included as core 
symptoms prior to popular dispute.7,8 Beyond direct symptoms; substance abuse, smoking, 
depression, suicide, poor physical health, eating disorders, and irritable bowel syndrome have 
been correlated with schizophrenia.1,9 For official diagnosis, the Diagnostic and Statistical 
Manual of Mental Disorders, has recommended the identification of two of the three core 
symptoms “for a significant portion of the time during a 1-month period” with some persistence 
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for at least 6 months.  Using these criteria, reports estimate that schizophrenia occurs in 
approximately 0.3-0.7% of the population, and incurring an economic burden of over 80 billion 
dollars a year.10,11 This burden is expanded from individual costs, as schizophrenia patients have a 
reduced average life expectancy (12-15 years), ongoing disability and psychotic relapses, 
increased rate of suicide, and are largely unemployed.12-15 
 
Antipsychotics and theorized mechanisms of action 
 Treatment of schizophrenia includes psychotherapy, counseling, and social support; although the 
primary focus of conventional disease management is antipsychotic pharmacotherapy.1 The first 
widely marketed antipsychotic, chlorpromazine, entered clinical use in 1952 and marked a 
watershed moment for psychotherapy.  Over time, treatment moved from invasive procedures 
(psychosurgery, electroconvulsive therapy, etc.) and inevitable long-term institutional care to 
outpatient pharmacotherapy.1,16,17 Since then, a wide variety of new antipsychotics have been 
created, representing some of the best selling drugs of all time.18 These drugs are split into two 
classes, typical (chlorpromazine, haloperidol, perphenazine, etc.) and atypical (clozapine, 
risperidone, olanzapine, aripiprazole, etc.).1 The difference in the two classes is atypicals are 
characterized by the reduced prevalence of extrapyramidal side effects (EPS) in extended use. 
EPS caused by antipsychotics can either be acute in early treatment, causing parkinsonism, 
akathisia, or dystonia; or cause tardive dyskinesia during long-term treatment. Because of their 
common prevalence, these neurological complications have been a major cause of burden for 
treatment courses and decisions.19 Exacerbating this burden, some reports have disputed the 
superiority and the reduction of associated adverse effects of atypical antipsychotics compared to 
typicals. Various meta-analysis studies have argued that atypicals show either non-significant or 
no improvement in reduction of EPS events.20-22 Furthermore, atypicals have induced other 
serious side effects, such as diabetes, weight gain, and agranulacytosis.23,24 These factors have 
caused some physicians to reexamine first-line treatment preference for atypicals. Regardless of 
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this contention, both classes are only efficacious against positive symptoms. Unfortunately the 
basis for these treatment’s antipsychotic effect, and general schizophrenia pathobiology, is still 
poorly understood and thus progress in characterizing pharmacotherapy limitations has been 
largely curtailed. However, newer tools have brought fresh insights into drug action and patient 
outcomes.1  
 The most prolific school of thought for schizophrenia pathology and antipsychotic efficacy is the 
dopamine receptor (DR) blockade hypothesis, as nearly all antipsychotics competitively block 
dopamine receptors to some degree.1,25 DRs are a class of G protein-coupled receptors which 
contribute to many neurological pathways responsible for cognition, pleasure, motor control, 
learning, memory, etc.26 There are two main families of DR’s with various localizations and 
densities in the brain and periphery: D1-like (D1, D5), coupling to Gsα which then activates 
adenylyl cyclase to increase intracellular cAMP; and D2-like (D2, D3, D4), coupling to Giα, which 
inhibits adenylyl cyclase and cAMP production.1,27  For many years, DR’s were implicated in the 
neurochemical and behavioral effects of antipsychotics, although it wasn’t until nearly 40 years 
after inception that these effects were validated with in vivo receptor occupancy studies via 
neuroimaging. 28-32 These studies reported greater dopamine occupancy of D2 receptors in the 
striatum of patients with schizophrenia compared to healthy individuals, which was then 
correlated to the presentation of positive symptoms.33 It has also been suggested that decreased D1 
receptor occupancy in the pre-frontal cortex (PFC) may cause impairments that result in negative 
and cognitive symptoms, and that overall dopamine system imbalance between the subcortical 
mesolimbic and mesocortical PFC are critical to schizophrenia pathology.34-36 In fact, keeping in 
mind all antipsychotics have no or modest selectivity for any member among the major DR’s, 
specific D2 receptor blockade strongly correlates to antipsychotic effect.37 However, there are 
some discrepancies between various antipsychotics and the suggested required occupancy levels 
for efficacy, depending on the binding kinetics and ability to induce high and low affinity states 
of DR’s.1 While some D1 selective antagonists have been studied, none have displayed 
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therapeutic benefit.38,39 Seemingly more promising are D1 agonists which have had mixed 
preliminary results.40 Beyond selective agents, some newer/atypical antipsychotics showing 
minor efficacy in reversing negative and cognitive symptoms and lower EPS risk, such as 
clozapine, have been suggested to increase dopamine in the PFC. While not engaging the D1 
receptors directly, instead this activity is hypothesized to come from 5-HT (serotonin) receptor 
antagonism/partial agonism (vide infra).33  
 The wealth of research on the dopamine hypothesis has undoubtedly cemented its association 
with schizophrenia; however, this theory is not without limitations. In haloperidol DR occupancy 
and other studies, some patients do not respond to treatment despite being far above clinical 
threshold levels, suggesting other mechanisms than dopamine imbalance/hypersensitivity.41 Two 
of the most prominent non-DR factors are 5-HT and glutamate receptors. 
 The link of 5-HT to schizophrenia was originally hypothesized in research comparing the disease 
to effects seen in lysergic acid diethylamide use, although inaccurately.42,43 However, serotonin 
has been reported to play a role in many processes disrupted in schizophrenia, including cognition, 
memory, perception, and aggression. Conventional knowledge of 5-HT receptors in 
schizophrenia follows from the findings of multiple receptor subtypes, their differential impact on 
various neurotransmitters, and antipsychotic binding. A similar research paradigm used to 
elucidate the DR blockade hypothesis (clinical efficacy, occupancy neuroimaging, and 
symptomatic correlation)  was used to interrogate the role of 5-HT receptors.44 The vast majority 
of the seven 5-HT receptor families are also G protein-coupled receptors, with the exception of 5-
HT3 which are ligand-gated Na+/K+ channels. These receptors have various activities in both 
modulating cAMP levels (Increase: 5-HT4, 5-HT6, 5-HT7; decrease: 5-HT1, 5-HT5) and increasing 
IP3/DAG (5-HT2 ). While nearly all of these receptors have shown antipsychotic binding, three (5-
HT1A, 5-HT2A, 5-HT2C) have been of considerable interest.45  Antagonism of 5HT2A receptors is a 
common characteristic for atypical antipsychotics, which paradoxically increases dopamine 
release in the PFC.46 In fact, these drugs have higher affinity for this receptor than DR’s. For 
5 
 
example, clozapine shows only modest occupancy of D2 receptors at clinical levels ( 20-67%) 
while exhibiting 80% occupancy of  5-HT2A.44 5-HT2C, which activates to inhibit dopamine 
release in the striatum, PFC, hippocampus, nucleus accumbens, etc., is commonly antagonized by 
atypicals.47 5-HT1A, a classic autoreceptor in the raphe nucleus and post synaptic receptor in other 
regions, has been shown to increase dopamine release in the PFC, hippocampus, and striatum 
upon activation.47,48 While the partial agonist activity of many atypicals on 5-HT1A fits general 
mechanism of action narratives for the PFC, the action in the striatum highlights the perplexing 
nature of the coordination of the dopaminergic and serotonin pathways.48 Adding yet another 
facet to this paradox is the growing evidence of antipsychotic efficacy without DR blockade via 
selective serotonin antagonists and reverse agonists.1 While the interaction of contradictory 
cascades resulting from 5-HT receptor blockade in the treatment of schizophrenia is still unclear, 
there is unquestionable clinical value in targeting these receptors. 
 Perhaps the most confounding evidence against the exclusive dopamine hypothesis is the 
potential role of glutamate receptors, specifically N-methyl-D-aspartate (NMDA) receptors. 
These receptors are a family of ionotropic glutamate receptors that are responsible for fast 
excitatory events in the central nervous system (CNS), with predominant actions in synaptic 
plasticity and memory.49 These receptors exist as tetramers of two NR1 and two NR2(A-D) 
subunits, with NR3(A-B) subunits substituting for NR1 to modulate activity. The heterogeneity 
of these receptors contributes to differential responsiveness and general effect on local receptor 
populations.50,51 Activation of these receptors requires the convergent events of ligand binding 
(two glycines and two glutamate molecules) and membrane depolarization,  allowing for the flow 
of positively charged ions (such as Ca2+) through the receptor-channel.52 Initial implications of 
aberrant glutamatergic activity in schizophrenia arose from physiological findings of disrupted 
cortical pyramidal neuron connectivity, these neurons primarily using glutamate as their 
neurotransmitter. Further investigation through postmortem brain expression analysis and 
neuroimaging highlighted the extent of altered expression of NMDA receptors in schizophrenia 
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patients.1 In many locations of the brain, expression analysis has yielded mixed results, partly due 
to brain sample heterogeneity, however some differential expression changes in the hippocampus 
and PFC have been reported.1 More definitive finding have been reported using in vivo single 
photon emission computed tomography (SPECT) neuroimaging, specifically fewer receptors in 
the hippocampus of untreated schizophrenics, consistent with expression analysis. These 
techniques are unable to differentiate reductions in receptor count and activation state.53 What 
may be the most important collection of evidence for the role of NMDA receptors in 
schizophrenia are studies examining the effects of phencyclidine (PCP) and ketamine, which are 
NMDA receptor antagonists. Both of these drugs simulate psychosis in healthy individuals while 
also worsening symptoms for patients. Positive, negative, and some cognitive symptoms have 
been reported in studies with ketamine.54 These drugs have been found to increase cortical and 
limbic extracellular dopamine levels.55,56. While haloperidol and olanzapine fail to block 
ketamine-induced psychosis, clozapine has been found to block the exacerbation of symptoms in 
patients given ketamine.54,57,58 Additionally, clozapine attenuates the reduction of NMDA receptor 
counts in patients by SPECT.59 These effects are hypothesized to come from clozapine’s 
polypharmacology, including glycine transporter blockade. Beyond isolated actions, the NMDA 
receptor has been found colocalized with D1 receptors in the PFC, the interplay of both possibly 
contributing to cognitive deficits, especially in working memory.60 Reports have also highlighted 
the effects of other schizophrenia implicated genes in NMDA activity, such as NRG1, ERBB4, 
DISC1, DAAO, and SRR, along with glutamate metabolism in glia.61 However, like dopamine and 
serotonin, the role of glutamatergic signaling in schizophrenia pathogenesis is still being 
elucidated.  
 While studies of serotonin and glutamate have brought some additional insight into treating 
negative and cognitive symptoms, conventional medications cannot consistently alleviate these 
maladies. Regardless of efficacy, newer agents still cause serious adverse events. Although 
clozapine has repeatedly demonstrated an idiosyncratic profile across many proposed 
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antipsychotic targets, its proclivity towards life-threatening agranulacytosis narrows its use as a 
treatment of last resort. The state of schizophrenia pharmacotherapy has prompted continued 
research for new antipsychotics. 
 
Modeling schizophrenia symptoms with animal behavior for drug discovery 
 In order to facilitate pre-clinical studies for the purpose of evaluating prospective drugs, 
researchers and regulators look to animal models for efficacy studies. These studies have deep 
limitations due to the lack of a characteristic genotype/phenotype/biomarker.  Additionally, none 
of these models can fully simulate the positive, negative, and cognitive symptoms of human 
schizophrenia (e.g. inability to sense whether or not a mouse is hallucinating). Despite the poor 
linkage to human efficacy (failures in phase II trials), they still provide needed testing funnels to 
triage novel compounds.  
 For each animal model, a number of behavioral and cognitive tests are used to evaluate deficits 
and alterations reflected in human patients and simulated by the model. Schizophrenia patient 
sensorimotor gating deficits have been observed through prepulse inhibition tests, a common 
method directly utilizable in rodents.62 Pharmacologically induced (either D2 agonist or NMDA 
antagonist) hyperlocomotion in rodents has been correlated to positive symptom presentation in 
patients notwithstanding an apparent lack of face validity, save psychotic agitation.63 Replicated 
cognitive impairments in patients have been assayed using T-maze experiments to test working 
memory, and the Morris water maze to study spatial learning and memory.64,65 Novel object 
location tasks are used to measure spatial memory and discrimination, while novel object 
recognition challenges measure recognition memory.66,67 Attentional set-shifting tests are used to 
evaluate attentional deficits that lead to reversal learning and discrimination impairments seen in 
patients.68 Negative symptoms are typically measured through social interaction and aggression 
of animals with their littermates.69,70 
 Initial rodent models used for drug discovery consistently predominantly of dopaminergic 
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alterations. For example, prospective antagonism of apomorphine-induced emesis or pre-pulse 
inhibition and amphetamine-induced hyperlocomotion directly seek changes in behavior by 
blocking induced D2 agonism. While these models have been somewhat useful in their predictive 
abilities, they do not necessarily model schizophrenia and are restricted in their validation of new 
agents to anti-dopaminergic efficacy.1 More recently, models incorporating neuronal 
development, decreased glutamatergic activity, and transgenic animals have garnered attention. 
 A number of methods have been used to create disrupted neuronal development in mice and rats. 
Methods such as malnutrition, infection with human influenza virus/ other viruses, X-ray 
irradiation, and exposure to toxins have been used to inhibit corticogenesis, disrupt neural circuits 
and neurotransmitter systems, and diminish the activity of developed neurons.1,71,72 The 
inflammatory agent polyriboinosinic-polyribocytidilic acid (PolyI:C) has been used to create 
dopaminergic and glutamatergic dysfunctions in mice through prenatal administration.73 However, 
the validity of these models is questionable as none of these methods have any evidence 
associated causative factors for disease pathology, with a possible exception for influenza 
infection. More relevant methods of altered neuronal development are stress models and neonatal 
lesions.1,74,75 Maternal and social isolation, among other stress-inducers, have been shown to 
create various hormonal and neurochemical changes, while also resulting in behavioral test 
changes, such as learning, hyperactive locomotion, and sensorimotor gating defects.62 These 
changes have been successfully reversed with conventional antipsychotics, including post-
development in adult mice.76-78 Lesions created on specific regions of the rat hippocampus that 
project to the PFC, the ventral hippocampus and ventral subiculum which correspond to the 
anterior hippocampus in humans (displaying structural abnormalities in patients), have resulted in 
a number of schizophrenia like behavioral phenotypes and aberrant development in the PFC. 
Interestingly, removal of  PFC neurons in rats with these lesions reverse some of the behaviors, 
implicating the necessity of PFC dysfunction in these schizophrenia-like characteristics.79-81 
These rats have shown glutamatergic and dopaminergic alterations, with some of the induced 
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behaviors being attenuated by antipsychotics.82 Some of these findings have been reproduced in 
non-human primates.83 
 In order to assess drug action on glutamatergic dysfunction, NMDA antagonism using ketamine 
and PCP has been used as an animal model for both non-human primates and rodents. Specific 
altered neuronal firing patterns in the nucleus accumbens, meso-limbic, and meso-cortical areas 
have been shown during these treatments along with various schizophrenia-like behaviors.84,85 
This model was used to discover LY-404,039 a novel metabotropic mGluR2/3 agonist, although 
the agent later failed phase II clinical trials.86,87  
 Finally, the use of transgenic animal models for drug discovery has been widely considered 
based on two schools of thought: 1) common disease/common allele (CD/CA) hypothesis in 
which pathology is driven by multiple mutations/expression deviations in low impact targets and 
2) common disease/rare allele (CD/RA) in which one mutation drives disease and is 
overexpressed/ knocked-out.1,88 However, the vast majority of drug discovery efforts driven by 
transgenic animal models consist of single gene approaches. Many schizophrenia-associated 
candidate genes have been used for models, including: NRG1, AKT1, COMT, DISC1, etc. In 
addition to targeting single genes, chromosome abnormalities (22q11.1 deletions) have be 
simulated in mouse models through microdeletions of mouse chromosome 16, which contains all 
of the respective genetic orthologs.74,89  
  The development of new transgenic animal models has been, perhaps, of greatest interest in 
recent years. This is likely due to the emergence of inexpensive whole genome sequencing and 
therefore the ability to process high-powered meta-analyses. New genes associated with 
schizophrenia are being discovered and their impact on development is being investigated. One 
import tool to measure the impact of these models is electrophysiology.74,90  
 
Relating electrophysiology to schizophrenia pathology  
  The essential units of the brain are neurons, which are electrically excited to release 
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neurotransmitters through action potentials which facilitate or inhibit neuronal signaling circuits 
controlling various functions. The electrical signals stemming from these activities have been 
used to investigate differences between schizophrenia patients and healthy individuals to identify 
possible aberrations in schizophrenia pathology. The cognitive aspects of the disease have been 
especially studied in the context of electrophysiology. Working memory is a vital component of 
higher cognitive functions, being defined as the ability to store information for some time in order 
to complete tasks that may be delayed.91 The prefrontal cortex (PFC) has been implicated to play 
a central role in working memory, as extracellular recordings in the PFC have shown that “a large 
fraction of prefrontal cortical neurons remain active after the cue and until the task is completed. 
Such activity can persist for several seconds without continued stimulation and has been proposed 
as the neural correlate of working memory.”91,92 This persistent activity is supported by a network 
of pyramidal neurons, the primary excitatory units of the PFC, processing various inputs and 
responding to glutamate and GABA (γ-aminobutyric acid) neurotransmitters.93 It is thought that 
pyramidal cells achieve this activity through low-frequency, non-adapting, neuronal discharges 
which are regulated by combined Na+ and K+ currents (Ih) via conversion to high-frequency 
discharges.91 This regulatory interaction causes the termination of trains of action potentials, or 
spike frequency adaptation. This is a common cortical firing pattern, which when synchronized 
within a network gives rise to electrical oscillations which can be detected via 
electroencephalography (EEG).94 Specifically, it has been shown that beta, gamma, and theta 
oscillations are indicative of neuronal activity in working memory cognition.95-97  
 Using EEG recordings, beta and gamma oscillation abnormalities have been detected in 
schizophrenia patients during working memory tasks, as compared to healthy individuals.98 In 
fact, changes in gamma power and synchronization have been reported in various studies using 
different cognitive tests. Many of these studies report contradictory data, and call into question 
the usefulness of the reductionist hypothesis focused on these oscillations. Reports on beta and 
alpha oscillations have suffered from similar issues. Theta frequency studies have been slightly 
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more consistent, with increased power observed in unmedicated patients, although even higher in 
clozapine-treated patients. It has been suggested that lower-frequency oscillations can affect 
gamma signals, thus perhaps a more holistic approach to EEG signals should be taken. 99 
 Beyond EEG, electrophysiological recordings for the purpose of finding useful biomarkers for 
schizophrenia drug discovery have extended to magnetoencephalography (MEG), which can 
complement EEG recordings, being more sensitive to cells tangential to the brain surface.  While 
these methods are still being developed, they are promising tools for evaluating antipsychotic 
intervention.100   
 
Potassium channels  
 Potassium channels are a very large family of channels involved in a variety of physiological 
roles.  Partitioned K+ ions are the principally determining factor for resting membrane potentials, 
as cell membranes are significantly more permeable to K+ than other cations due to the strong 
chemical gradient for intracellular cations to move out of the cell through K+ leak channels 
(150mM intracellular K+ vs. 5mM extracellular K+). Potassium channels use these gradients to 
regulate various processes including muscle contraction, hormone secretion, and neurotransmitter 
release, etc. Unsurprisingly, these functions are controlled by a large family of K+ channels with 
several common features. All K+ channels are tetrameric in structure, either consisting of 
homologous subunits or heteromers. Each channel monomer includes a hydrophobic region, a 
water-filled central cavity, and a pore loop, containing a selectivity filter which allows the 
channel to discriminately pass K+ ions without promiscuous transport of other ions such as Na+ 
(having a 0.38 Å smaller radius).101 The signature amino acid sequence for the selectivity filter is 
highly conserved in K+ channels (TVGYG), although this is not always the case (vide infra). This 
selectivity filter is thought to operate by desolvating the ion by mimicking the K+ solvation shell 
via aligning the selectivity filter residues’ respective carbonyl oxygens to form a square anti-
prism. However, this mechanism is still debated. 102 103 There are four major families of 
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potassium channels: calcium activated, tandem pore domain, inwardly rectifying, and voltage 
gated. 
 Calcium activated K+ channels are either directly activated by calcium or are structurally related. 
These channels are comprised of α subunits with 7 transmembrane α-helices, a pore forming loop, 
and a large intracellular region for calcium binding. Transmembrane regulatory subunits that 
interact with the α tetramers, called β subunits, can either inhibit or facilitate activation of the 
channel. There are three major families of human calcium activated K+ channels: BK, IK, and 
SK.104 BK channels have large conductance for K+ and are also activated by voltage. These 
channels have been of interest as potential drug targets for stroke, overactive bladder, and opioid-
induced respiratory depression.105-107 IK channels are characterized by their intermediate 
conductance and are important for vasodilation of capillaries and neutrophil phagocytosis.108,109 
SK channels have small conductance and are voltage insensitive. These channels are thought to 
be involved in synaptic plasticity and are widely expressed in the central nervous system.110 
 Tandem pore domain channels are also known as “leak channels”, being subject to Goldman-
Hodgkin-Katz flux rectification. These channels have α subunits with only four transmembrane 
domains with two pore loops per unit and form functional dimers. These channels are heavily 
involved in maintaining resting membrane potential.111  
  Inwardly rectifying channels have two transmembrane domains and a single pore loop per α 
subunit and consists of seven distinct families. These channels are “inwardly-rectifying” in the 
sense that they conduct K+ more efficiently into the cell rather than out of the cell. This action 
brings the cell back closer to resting membrane potential post-activation which is an important 
contribution to regulating neuronal activity. Inward rectification is distinct from the majority of 
potassium channels which typically facilitate passage of K+ out of the cell, and is achieved by the 
presence of polyamines and magnesium that selectively block outward passage of K+ at positive 
membrane potentials.112-114 Alternatively, activation of the inward conductance is trigged by the 
binding of an agonist, phosphatidylinositol 4,5-bisphosphate (PIP2).115 These channels are 
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involved in prolonging the cardiac action potential, regulating nitric oxide synthase, excretion of 
K+, neuronal activity, and insulin release. Logically, these channels have also been implicated in a 
number of different diseases.112  
 Voltage-gated K+ (Kv) channels are similar to calcium-activated channels in that they have six 
transmembrane domains and a pore loop per subunit. However, each of these channels also has 
large intracellular N and C terminus sequences that make up various important domains for 
channel gating and kinetics. Some channels, such as the KCNAB, KCNE, and KCNIP families 
are known to have β subunits which modulate activity.116 The Kv channels are especially 
important in repolarizing cells during action potentials and have been the focus of many drug 
discovery efforts.117 
 
Voltage-gated potassium channel electrophysiology techniques for drug discovery 
 In order to study Kv channels, especially for the purpose of drug discovery, one must be able to 
monitor their activity: the conductance of K+. The “gold standard” for observing these activities is 
the patch-clamp, voltage clamp method, discovered by Nobel Laureates Erwin Neher and Bert 
Sakmann.118  This method consists of using a glass micropipette to record electrical cell signals, 
referenced by a ground in an aqueous bath mimicking extracellular conditions. Suction is applied 
through the pipette to create a high resistance seal, typically greater than 1 gigaohm, to filter noise 
and keep the membrane-pipette seal intact. Depending on the purpose of the experiment, 
recordings can be taken with the pipette simply on the cell (on cell), removed to examine single 
channels (inside-out or outside-out), or perforating the cell to monitor entire cellular activity 
(whole-cell).119 The vast majority of Kv channels are monitored for drug discovery using whole-
cell patch clamp technique in order to maximize signal where channels are 
activated/deactivated/inactivated by varying voltage inputs through automated protocols.120 
However, this also comes at a disadvantage in that the solution inside of the pipette begins to 
dialyze into the cell, creating artificial intracellular conditions. Therefore, the internal pipette 
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solution is typically formulated to mimic the intracellular solution as much as possible to limit 
extraneous variables.121  
 For dose-response and kinetic assays, most channels are recapitulated via recombinant channel 
expression in immortalized cell lines, typically Human Embryonic Kidney (HEK 293) or Chinese 
Hamster Ovary (CHO-K1). However, each of these cell lines may have various endogenous 
channels, possibly confounding recordings if not tested. 122 Expression in these cells lines have 
been carried out in numerous ways including transient transfections and transductions through 
BacMam virus, or stably transfected via plasmid/linearized DNA or lentivirus integration.123,124  
 Unfortunately, the use of voltage clamp for drug discovery, especially in early-stage hit 
discovery, is time-consuming and prone to variability. Efforts to automate this process, either 
through indirect measurements or true voltage-clamp, have yielded techniques more amenable to 
high throughput screening and lead optimization. Such procedures include detecting ions that 
pass through Kv selectivity filters (Rb+ and Tl+) or true voltage control through automated patch 
clamp (APC).125-127 However, each of these techniques have limitations as compared to traditional 
manual voltage clamp so initial findings must be confirmed by traditional methods.128 
 
The human ether-a-go-go related gene and Kv11.1 channels 
 The most notorious of all potassium channels, if not all channels in the context of drug discovery, 
is Kv11.1, a Kv channel encoded by the gene KCNH2, also known as the human ether-à-go-go 
related gene (hERG). This channel earns its acclaim for an idiosyncratic ability amongst ion 
channels to promiscuously bind small molecules, especially pharmaceuticals, which has caused 
the addition of FDA mandated black box label warnings and removal of many drugs from the 
market. This is due to Kv11.1’s central role in a cardiac repolarization current called IKr, which 
results in a fatal arrhythmia called “torsades de pointes” upon channel blockade. However, 
Kv11.1 has been shown to play other important roles in other tissues like the brain, and has been 
implicated in schizophrenia pathology.128,129 
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 Discovered in 1969 by William Kaplan and William Trout through mutational gene mapping in 
Drosophila Melanogaster, the name Ether-à-go-go was coined as a reference to dancers at the 
Whiskey a Go-Go, a popular nightclub on the Sunset Strip in West Hollywood, California, where 
many famous artists, such as Van Halen, The Doors, Metallica, Guns N’ Roses, and Alice Cooper, 
played gigs early in their careers. When ether-à-go-go (EAG) mutated flies were put under the 
influence of ether, their legs would shake noticeably slower than other Shaker locus mutations, 
analogous to a popular dance exhibited at the Whiskey a Go-Go during the 1960’s.130 Of note, 
this same paper also identified the classic channel typology gene, Shaker.131  
 Kv11.1 channels are expressed in a number of different tissues in humans, including the 
hippocampus, PFC, small intestines, gallbladder, pancreas, and tumors.128 In neurons, Kv11.1 
channels have been shown to be important for spike-frequency adaptation and burst 
duration.132,133 However, Kv11.1 is best known for its role in the heart, specifically in atrial and 
ventricular myoctyes, for its leading contribution to rapid delayed rectifier potassium currents (IKr) 
in cardiac repolarization. 134,135 This current controls the duration of phase 2 (or plateau) in the 
cardiac action potential. IKr is vital for coordinating proper heart contraction, antagonizing cardiac 
depolarization from premature beats i.e. rhythm, as monitored by the QT interval via 
electrocardiogram. Blockade of Kv11.1 channels increases risk of deadly cardiac arrhythmias, 
such as torsades de pointes. Kv11.1 channels also are expressed in sinoatrial and atriventricular 
nodes where they make a minor contribution to pacemaker activities.136-138 
 In 1994, the human ortholog of the EAG channel was identified and cloned, having sequence 
similarity to both Kv channels and cyclic nucleotide-gated channels.139 Thus, the gene encoding 




















Figure 1.1 KCNH2 gene location, transcripts, and basic KCNH channel structure. a, View 
of chromosome 7 q36.1. KCNH2 encodes for five unique transcripts. b General KCNH channel 




chromosome 7 (NG_008916) and contains 15 exons, transcribing the reverse strand to yield a 3.3 
kb transcript KCNH2-1a. There are two internal alternative transcription start sites, leading to two 
truncated transcripts, KCNH2-1b and KCNH2-3.1. Additionally, two unique premature stop 
transcripts have been identified (Figure 1.1a).128 
 Translation of KCNH2-1a results in an 1159 amino acid protein hERG or Kv11.1 or Kv11.1-1A.  
Kv11.1-1A is a member of the Kv superfamily of potassium channels. Like other Kv channels, 
Kv11.1 contains six α helical transmembrane domains (S1-S6), and a pore loop. S1-S4 create the 
voltage-sensing domain while S5-6 and the poor loop constitute the pore domain.128 The voltage-
sensing domain responds to changes in the transmembrane electric field and changes 
conformation to electromechanically influence the opening of channel at the activation gate, 
residing at the interface of the channel entrance and the cytoplasm.140 The pore loop facilitates K+ 
transport through the channel (vide supra), yet has a significantly different selectivity filter than 
typical K+ channels, as its sequence is SVGFG (opposed to TVGYG).141  
 Additionally, Kv11.1-1A has long intracellular N and C termini that comprise the vast majority 
of the amino acid sequence. The N-terminal region makes up the Per-Ant-Sim (PAS) domain, and 
the N-terminal cap; while the C-terminal region makes up the C-linker and the cyclic nucleotide-
binding homology domain (CNBHD) (Figure 1.1b).128  
 The PAS domain has been implicated in controlling the hallmark slow-deactivation rate kinetics 
of Kv11.1 channels (vide infra), but also in folding, assembly, and stabilization of the tetrameric 
channel structure.142-144 While it is not necessary for normal trafficking or stabilization, when it is 
present, the N-terminal cap must also be intact for normal channel function and trafficking. The 
N-terminal cap contains an amphipathic helix that interacts with small hydrophobic region of the 
PAS domain to stabilize the channel and thus influences trafficking.145 The C-linker is a 
structurally folded domain that connects the CNBD to the transmembrane pore areas. The CNBD   
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is thought to interact with the PAS domain and N-terminal cap to assist in modulating channel 
connects through interaction via a small hydrophobic patch on the CNBD as hypothesized from 
analogous channels.146 Unsurprisingly, many mutations in these cytoplasmic regions cause altered 
channel characteristics and disease (vide infra).144,147 While Kv11.1-1A has not been crystalized 
for structural analysis, the cytoplasmic residing domains have been the study of various 
crystallography and nuclear magnetic resonance (NMR) studies.148,149 
 Kv11.1-1A channels are synthesized and trafficked similarly to other K+ channels and integral 
membrane proteins. mRNA is translated in the cytosol where a transmembrane signal is detected, 
pulling the translational machinery to the endoplasmic reticulum (ER) where the nascent peptide 
is strung through the ER membrane via translocation mediating proteins and lipids.  Chaperone 
proteins bind to folding intermediates, especially the HSP40, HSP70, and HSP90 families, to 
prevent misfolding via binding to exposed hydrophobic regions in the intermediate channels.128,150 
Mutant channels are typically bound by chaperones for longer periods of time and eventually lead 
to proteasomal degradation. The regulation of trafficking versus degradation is strongly 
controlled and widely studied. A contemporary model of the Kv11.1-1A quality control pathway 
suggests that nascent channel peptides are bound by Hsp40 family members DNAJA1/2 which 
stimulate Hsp/Hsc70 binding via ATP hydrolysis. Various nucleotide exchange factors drive 
Hsp/Hsc70 binding cycles that facilitate folding along with the Hsp40’s. This reaction cycle is the 
major checkpoint of Kv11.1-1A quality control towards either degradation or eventual trafficking 
to the cell surface. DNAJA1 and Hsp70 are thought to promote ER exit by recruiting Hsp90 and 
Hsp-organizing protein (HOP), which release Hsc70 from nascent channels allowing Hsp90 and 
FKBP38 to complete the folding process. Conversely, DNAJA2 is thought to promote Hsc70 and 
recruit CHIP, a soluble E3 ubiquitin ligase. CHIP, and possibly other E3 ligases, ubiquitinylate 
the misfolded channel which is then directed towards proteasome degradation.151-154  Kv11.1-
1A channels also contain a number of “RXR” motifs that signal for ER retention, although these 
sequences are typically hidden in well folded channels, creating another layer of folding 
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control.155 Additionally, nascent channels are N-linked glycosylated at Asn598 and, possibly, 
Asn629 in the ER, leading to a 10 kDa addition in molecular weight (125 kDa vs 135 kDa).156 
This glycosylation event creates “core glycosylated” (CG) channels.  If properly folded, the 
channel is trafficked to the Golgi apparatus where the nascent channel is glycosylated a second 
time, adding an additional 20 kDa in molecular weight. Channels that have been glycosylated 
twice are referred to as “fully glycosylated” (FG), which then exit the Golgi and traffic to the 
plasma membrane. At the plasma membrane the channels can interact with a variety of different 
proteins, including ubiquitin ligases which can facilitate ubiquitin –mediated lysosomal 
degradation (and in some cases, proteasomal) via endocytosis and retrograde translocation.128,157 
 The two most studied alternatively transcribed variants of KCNH2-1a are KCNH2-1b and 
KCNH2-3.1. KCNH2-3.1 will be discussed further below as it is the main channel of interest in 
this study. Translation of KCNH2-1b synthesizes an N-terminally truncated channel with amino 
acid sequence length of 819 called Kv11.1-1B.128,158 While able to form functional homotetramers 
(tetramer assembly occurs in the ER) with poor activity and trafficking impairments, Kv11.1-1B 
is predominantly present as part of a heterotetramer with Kv11.1-1A. This poor trafficking and is 
due to the presence of an additional “RXR” ER retention amino acid sequence unique to the 
Kv11.1-1B channel, although the altered kinetics are likely due to the absence of the PAS domain 
and N-terminal cap. However, upon heterotetramer formation with Kv11.1-1A, this signal is 
shielded, promoting exit from the ER. Kv11.1 heterotetramers also display changes in channel 
kinetics and is thought to primarily depend on subunit stoichiometry.155,159  
 Conceptually, it is useful to think of the Kv11.1 channel existing in three states: closed, opened, 
and inactivated.  The transition from closed to open is referred to as activation, open to 
inactivated as inactivation, inactivated to open as recovery from inactivation, and opened to 











Figure 1.2. Kv11.1 channel states and gating. a, Kv11.1 channels transition between closed, 
opened, and inactivated states. b, Kv11.1 induced currents via voltage-clamp protocols. Note 
channel gating in response to the voltage steps and voltage-dependent current directionality of 
channel reactivation.   
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 Unique from other Kv channels, Kv11.1-1A channels transition between opened and closed 
states slowly, needing almost an entire second to fully open/close. Transitions between opened 
and inactivated are much faster, on the order of milliseconds. These voltage-dependent properties 
are essential for normal action in cardiac repolarization (vide infra).128  
 Just as normal kinetics is important for proper channel functional, equal attention has been 
brought to the role of trafficking in overall contributions to cellular action. The most prolific 
examples of Kv11.1-1A function in the context of trafficking concerns are congenital mutations 
in the channel causing Long QT Syndrome, type 2 (LQTS2). It has been found that patients with 
LQTS2 have various mutations in KCNH2, causing either/or premature stop codons, misfolded or 
unstable channels, or altered kinetics/intrinsic activity.128 Most of these mutations occur in the 
either the pore or PAS domains and have led to the discovery of their relative importance in 
trafficking and channel stability.144 Effects in trafficking have been studied by exploiting the large 
size differences in the glycosylated states of channels by western blot. Since the ER is the major 
checkpoint in Kv11.1-1A trafficking, and ER retained channels are not glycosylated a second 
time, one can use the relative abundance of CG and FG channels to diagnose and assay changes 
in trafficking. This technique has led to the identification of the Kv11.1-1A quality control 
pathway, pharmacological agents, and other factors that affect or rescue trafficking.128  
Kv11.1-1A channels have been found to interact with a number of other proteins that can either 
regulate its activity or expression. Other K+ channels (and possibly their β subunits), such as 
KCNE1/2, KCNQ1, and KCR1, can associate with Kv11.1-1A and modulate its activity. Various 
kinases have been shown to posttranslationally phosphorylate Kv11.1-1A, influencing gating 
properties along with biogenesis. This includes PKA via cAMP signaling, PKB via PIP3 signaling, 
and PKC through diacylglycerol signaling. Tyrosine kinase SRC has been shown to complex with 
Kv11.1-1A channels.128 
 As previously mentioned, Kv11.1-1A channels have been shown to promiscuously bind to small 
molecules. In conjunction with its vital role in cardiac repolarization, this phenomenon has 
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marketed Kv11.1-1A as one of the largest anti-targets in drug discovery.160 While not the first 
drug to be removed from market due to effects of Kv11.1-1A blockade, the antihistamine 
terfenadine (Seldane®) arguably brought pharmacologically induced QT prolongation via IKr 
inhibition to the forefront of regulatory attention.161 Approved in 1985, patients prescribed 
terfenadine were later found to be at increased risk of ventricular arrhythmias, especially those 
concomitantly prescribed CYP3A4 inhibiting drugs such as macrolide antibiotics. In the early 
1990s it was found that terfenadine inhibited IKr currents and by 1996 it was shown that it directly 
inhibited Kv11.1-1A channels. Due to these studies and the introduction of less toxic 
antihistamines, terfenadine was withdrawn from the market in 1998.162 Since then, a number of 
drugs have been withdrawn or given black box label warnings, including grepafloxacin, 
astemizole, cisapride, haloperidol, ziprasidone, amitriptyline, and many other CNS drugs.163 
Behind this promiscuous binding of a wide class of drugs lays two main factors: two key aromatic 
residues in the channel pore (Tyr652 and Phe656) and C-type channel inactivation.128,164,165 After 
the channel has opened (a requirement for promiscuous molecule binding) the topology of the 
Kv11.1-1A channel pore allows for multiple binding modalities, although high-affinity 
compounds are typically anchored by interactions with either Tyr652 or Phe656 (or both.)166  
Mutagenesis screens have reported the necessity of an aromatic side chain and hydrophobic side 
chain at these positions, implicating π-π stacking or π-cation interactions with exogenous 
compounds (Figure 1.3).  
 Indeed, the generalized Kv11.1-1A pharmacophore of many high-affinity block compounds 
includes a basic amine or high logP-driving structures. Polar residues near the N-terminal of the 
pore helix have also been shown to drive compound-specific binding interactions in the pore, 
although these are highly conserved across multiple Kv channels. Tyr652 and Phe656 are not 
conserved, giving rise to the idiosyncratic binding of Kv11.1-1A.164,166,167 Interestingly, Kv10.1 
has both of these residues in analogous positions, yet does not display the same promiscuous 






















Figure 1.3. Key aromatic residues in the Kv11.1 channel pore mediate high-affinity 
promiscuous binding.   
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result from the lack of rapid C-type inactivation in Kv10.1. C-type inactivation contrasts from N-
type in that, instead of closing the channel via an internal-TEA-sensitive cytoplasmic “ball and 
chain” inactivation particle, the channel inactivates by closing the selectivity filter and stabilizing 
this conformation. In fact, chimeric Kv10.1 channels, having Kv11.1-1A pore and S6 domains, 
exhibit high-affinity promiscuous binding.165,168,169 However, the contributions of C-type 
inactivation have been quantitatively shown to be of less importance than the aromatic pore side-
chains and not all drugs prefer to bind to the inactivated state.170,171 Beyond factors that drive 
affinity for the Kv11.1-1A channel, their contributions are exacerbated by drug trapping inside 
the pore. Drug trapping artificially reduces inhibitor off rates due to the closure of the channel 
during repolarization.128  
 IKr blockade-induced QT prolongation is especially common among antipsychotics, but the 
pertinence of Kv11.1-1A to schizophrenia extends beyond adverse event risk.172 Neuronal 
expression of Kv11.1-1A (and other related EAG/ERG channels) has been found in the cortex, 
hippocampus, substania nigra, thalamus, hypothalamus, and cerebellum. On a cellular level, 
Kv11.1-1A channels are expressed in the axon, dendrites, and cell body. As mentioned previously, 
Kv11.1-1A channels have been shown to be involved with burst firing, which regulates prolactin 
release in pituitary lactotropic cells. Kv11.1-1A channel inhibition in cerebellum Purkinje 
neurons has been reported to increase excitability and flatten spike-frequency adaptation. 133,173 
However, of great interest is the role of Kv11.1-1A channels in dopaminergic neurons. These 
channels contribute to calcium-independent afterhyperpolarization (AHP) currents. Antipsychotic 
blockade of Kv11.1-1A currents in mid-brain dopaminergic neurons also significantly reduces 
post-stimulus inhibitory period end the end of an action potential train, increases excitability, 
being implicated in dopamine release.173,174 Furthermore, these studies have suggested Kv11.1-1A 
channels reduce depolarization block of these neurons, the elongation of which being a common 
effect of antipsychotics associated with efficacy. Therefore, it has been suggested that Kv11.1-1A 
blockade in the CNS contributes to the therapeutic effects of certain antipsychotics and that these 
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channels may be novel antipsychotic drug targets.175 
 
KCNH2-3.1 and Kv11.1-3.1 
 In 2009, a new KCNH2 isoform was reported by Huffaker et. al.176 Using family-based 
association test analyses (FBAT) for single nucleotide polymorphisms (SNPs) of gene-based 
haplotypes in 170 families of European descent having an offspring with schizophrenia, they 
found a number of closely localized schizophrenia-associated SNPs in 7q36.1, specifically the 
KCNH2 and NOS3 regions. The most statistically significant SNPs were located in the KCNH2 
gene. A selection of these SNPs were analyzed in expanded, independent family datasets and 
triaged for further analysis. Using a meta-analysis for all of these datasets, a number of SNPs in 
an intronic region of KCNH2 were found to be significantly associated with schizophrenia. 
Knowing that KCNH2 was highly expressed in brain regions important in schizophrenia 
pathology (dorsolateral PFC “DLPFC”, hippocampus), three SNPs were found to be associated 
with lower IQ, slower/inefficient cognitive processing, increased cortical engagement, and 
decreased hippocampal structure in healthy controls via fMRI and cognitive testing studies. These 
phenotypes are associated with genetic risk of schizophrenia, general cognitive deficit, and 
impaired hippocampus/DLPFC function.177-180  
 In attempts to reduce these finding to mechanism, it was found that KCNH2-1A mRNA was 
reduced in the PFC and hippocampus in patients with schizophrenia, although this was not 
associated with specific SNP expression. However, RNA sequencing from the DLPFC  of post-
mortem brains obtained from schizophrenia patients was able to identify an endogenous transcript 
with a start site extending from exon 3 (without exons 1 or 2). This transcript corresponded to an 
N-terminally truncated isoform of Kv11.1-1A, missing 102 amino acids. This transcript, coined 
“KCNH2-3.1”, was recombinantly expressed in HEK 293 cells, displaying a size difference 
compared to full length protein by western blot. Interestingly, western blot in human DLPFC and 
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rhesus monkey show bands of both sizes, suggesting comparable expression of the full length and 
truncated. However, KCNH2-3.1 was not found to be present in other mammals besides primates. 
Transcript expression of KCNH2-3.1 was subsequently shown to be brain specific, being 
expressed three orders of magnitude more in the hippocampus and fetal brain than in the heart. 
Additionally, while expression differences and developmental patterns of KCNH2-1A and 
KCNH2-3.1 were similar in most brain regions in postnatal samples, KCNH2-3.1 expression in 
fetal brain samples were found to be expressed much higher that the postnatal level.  Importantly, 
the ratio of KCNH2-3.1 expression to KCNH2-1A expression was 2.5-fold higher in 
schizophrenia patients as compared to controls. Finally, increased KCNH2-3.1 expression was 
significantly associated with the identified risk SNP’s (rs3800779 being the most prominent) in 
both patients and controls, suggesting a biological mechanism for schizophrenia risk.  
 Whereas Kv11.1 channels have been implicated in neuronal firing processes and regulation, 
Huffaker et. al investigated the functional role of the resulting translational product from the 
KCNH2-3.1 transcript, Kv11.1-3.1. Using whole-cell voltage clamp in transfected HEK 293 cells, 
Kv11.1-3.1 showed rapid deactivation, faster activation, and decreased hyperrepolarizing tail 
current amplitude as compared to Kv11.1-1A. Cells co-expressed with both channels showed 
intermediate phenotypes for kinetics and amplitude. Kv11.1-3.1 was transfected into primary rat 
cortical neurons, which presumably formed heterotetramers with endogenous Kv11.1-1A 
channels, and were found to exhibit similar kinetics in the pure, subtracted currents. Using current 
clamp protocols, Kv11.1-3.1 transfected neurons showed greater excitability via increased spike 
frequency. Kv11.1-1A transfected neurons showed behavior similar to transfected cells. 
Additionally, this excitability exhibited a non-adapting pattern, suggesting changes in spike-
frequency adaptation important for PFC function and cognition.176 
 This seminal work was quickly followed by a report validating the association of SNPs in the 
KCNH2 locus, including rs3800779, using an independent, Turkish male dataset.181 Hashimoto et 
al. also used rs3800779 to confirm KCNH2 association with schizophrenia in a meta-analysis of 
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five independent ethnic groups along with recruited Japanese subjects. In this report they used 
similar cognitive tests with recruited controls and patients and confirmed results found in 
Huffaker et al.182 Recently, additional SNP’s in the bordering locus between KCNH2and NOS3 
have been shown to be significantly associated with social memory, although the pertinence of 
these finding to schizophrenia has yet to be determined.183 The same NIMH group examined 
pharmacogenetic relationships between risk SNP’s and treatment outcome from a previous effort 
to gather genetic, clinical, and symptomatic datasets in the context of antipsychotic treatment: 
Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE).184,185 In the CATIE study, 
schizophrenia patients were randomly prescribed various antipsychotics and examined for 
outcomes using the PANS scale during regular intervals for 18 months.5,185 In the follow up study 
seeking associations between KCNH2-3.1 risk SNP’s and treatment outcomes, it was found that 
patients homozygous for the previously reported SNP, rs1036145, were more likely to respond to 
treatment for the reduction of positive symptoms with  no difference for negative symptoms, but 
were also one-fifth as likely to discontinue olanzapine (although this result was underpowered). 
SNP rs3800779 did not show any significant differences between patients besides a generally 
more positive outcome regardless of treatment.186  
 Apart from the growing evidence of clinical significance, more studies into the cellular and 
mechanistic characteristics of the Kv11.1-3.1 channel were also studied. By stably expressing 
Kv11.1-3.1 in CHO cells, containing few endogenous K channel currents, a purer approach to 
determine the gating differences, as compared to Kv11.1-1A, could be taken.122,187 Using 
established voltage protocols to examine Kv11.1 gating kinetics (activation rate as determined by 
envelope of tails, voltage-dependent steady state activation, deactivation rate, inactivation, etc.), 
Heide et al. confirmed the hallmark rapid deactivation rate although reported similar rates of 
activation and voltage-dependence of steady state activation in contrast to Huffaker et al.128,176 
However, this study also demonstrated that Kv11.1-3.1 channels have slower inactivation at 
depolarized membrane potentials, leading to greater current flux at these states. In the scope of 
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schizophrenia, these results suggest that greater populations of Kv11.1-3.1 channels leads to less 
current accumulation, curtailing typical Kv11.1-1A inhibition of long action potential trains, 
suggesting a mechanism behind the increased excitability found in Huffaker et. al.176,187 Ke et al. 
were the first to formally report the trafficking defect of Kv11.1-3.1 channels, citing the absence 
of most of the PAS domain, yet showing this domain was not necessary for proper trafficking or 
activity, displaying the efficacy of a complete N-terminal truncated Kv11.1-1A mutant Δ2-135. 
From this report it was speculated that the N-terminus of Kv11.1-3.1 was likely not folded and 
would be recognized as unfolded and marked for degradation. The report also suggested that a 
complete PAS domain allows for proper trafficking with an N-terminal cap domain, thus 
intermediate residues, as found in Kv11.1-3.1, are not sufficient. Interestingly, Kv11.1-3.1 was 
shown to form heterotetramers with both Kv11.1-1A and Kv11.1-1B channels.145 In a 
continuation of the work at the Vandenberg group, Heide et al. examined the expression of 
KCNH2-3.1 mRNA via in-situ hybridization in post-mortem DLPFC in healthy controls and 
schizophrenia/schizoaffective patients stratified by SNP analysis. KCNH2-3.1 mRNA was found 
in both large and small neurons in the DLPFC. In the combined group of 
schizophrenia/schizoaffective patients, a significant increase in mRNA was found as compared to 
healthy controls in layer III/IV small neurons only while confirming increases of fold change 
expression across SNP alleles.188 In collaboration with members of the NIMH group, Heide et al. 
screened common antipsychotics on differential abilities to selectively inhibit Kv11.1-3.1 over 
Kv11.1-1A. Using the stably expressing CHO cell line, it was found that risperidone, and not its 
active metabolite 9-hydroxyrisperidone (paliperidone), was two-fold selective for Kv11.1-3.1, 
with an IC50=200 nM (Kv11.1-1A IC50=508 nM). Noting the difference in selectivity difference 
between risperidone and paliperidone, it was found that KCNH2-3.1 increasing risk SNP patients 
with “poor metabolizer” status (due to cytochrome P450 polymorphisms, etc.) exhibited a better 
treatment response to risperidone than other drugs.189 
 In order to validate Kv11.1-3.1 as a target for drug discovery for the treatment of schizophrenia, 
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a transgenic mouse model was developed and characterized for behavioral deficits.190 Using a 
“tet-off” NSE promoter (for specific neuronal expression) transgene, a mouse model was 
developed that overexpressed KCNH2-3.1 in the PFC, hippocampus, striatum, and cerebellum. 
As adults, these mice were shown to exhibit impaired theta burst stimulation long-term 
potentiation (LTP), suggesting functional hippocampal impairment. Impaired basal synaptic 
transmission in adult mice was also observed. Primary pyramidal PFC neurons from transgenic 
mice were shown to have increases firing rates/increased excitability compared to wild-type mice 
along with the hallmark rapid deactivation rates. While the transgenic mice did exhibit 
characteristics of Kv11.1-3.1 expression as predicted in previously reported cellular models, these 
mice were also tested in t-maze working memory and object location spatial memory challenges. 
In the t-maze test, adult transgenic mice were found to be less accurate in 4-s delay trials, 
suggesting impaired working memory that requires a functional PFC.  During the object location 
task, transgenic mice were shown to have no preference for displaced objects, suggesting 
impaired hippocampal memory function. While the hippocampal electrophysiological deficits 
were not present in juvenile mice, reduced expression in transgenic mice via doxycycline 
treatment (triggering the “tet-off”), reversed LTP and novel object location deficits to being 
statistically indistinguishable from wild-type mice. While there may be a possible developmental 
effect, this report also suggests that adult treatment for Kv11.1-3.1 contributing pathology may be 
a possibility. Most importantly, this work established a working in-vivo model for Kv11.1-3.1 
contributions to schizophrenia-associated deficits and behaviors, a necessary tool for drug 
discovery. 
 While some basic characterization of the channel has been reported along with a promising 





Scope of studies 
 New pharmacological agents for the treatment of schizophrenia are needed. Over the past 6 years, 
Kv11.1-3.1 has presented itself as a possible therapeutic target given the genetic, clinical, and 
transgenic mouse model findings. However, key questions remain: is it possible to get therapeutic 
effects in the brain without untoward effects on the heart? Does Kv11.1-3.1 apply a negative 
effect to the cell (requiring inhibition) or does it merely exist in the absence of a required positive 
(requiring activation)? The ultimate aim of this work is to create a tool compound for a drug 
discovery campaign that will allow us to investigate the pathology of Kv11.1-3.1 and be used as a 
benchmark for determining CNS efficacy and cardiovascular safety. However, the lack of high 
throughput screening and other assay infrastructure hinders any prospective drug development. 
While Kv11.1-1A channel assays have been well established in a variety of methods, including 
APC, Kv11.1-3.1 exhibits especially poor trafficking and low assay signal. In order to alleviate 
these issues and progress onto translational efforts, basic inquiries into the nature of these 
trafficking deficits must be taken. Upon trafficking rescue, subsequently developed assays may be 
used to not only drive medicinal chemistry and screening, but also to investigate a wider selection 






Kv11.1-3.1 Exhibits a Unique Trafficking Deficit that is Rescued 
Through Proteasome Inhibition for High Throughput Screening 
 
Introduction 
 The discovery of a small molecule that could selectively modulate Kv11.1-3.1 activity presents 
many challenges. The most apparent issue is channel homology to Kv11.1-1A (hERG), the 
primary channel involved in cardiac IKr currents and frequent anti-target causing arrhythmia, 
Long QT Syndrome, and torsades de pointes.128 hERG channels have also been implicated in 
processes such as midbrain dopaminergic bursting and epilepsy, which may present unique 
challenges as Kv11.1-3.1 and Kv11.1-1A channels are expressed at similar levels in the brain and 
have been shown to form heterotetramers in cell models.145,174,176,191 To develop novel modulators 
of this channel for psychiatric indications, great care must be taken to identify molecules with 
selectivity over the Kv11.1-1A form of the channel to avoid cardiac and neural toxicities. Robust 
screening methods with consistently large signals are required to rapidly discover promising tools; 
however, Kv11.1-3.1 presents significant obstacles to efficient screening.125,192 While recording 
from cells overexpressing Kv11.1-3.1 is possible, previous studies have shown trafficking defects 
and low current densities comparable to Long QT Syndrome 2 (LQTS2) Kv11.1-1A mutants, 
which makes high throughput screening impractical.187 Similar to Kv11.1-3.1, many of these 
LQT mutants contain mutations and deletions in the PAS domain, also resulting in rapid 
deactivation kinetics in HEK 293 cell models.128,144,193,194 These kinetic effects are likely due to 
the loss of PAS domain interactions with the amphipathic helix containing N-cap and C-terminal 
nucleotide binding domain (cNBD).146,195,196 While it has been demonstrated that complete PAS 
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domains are not necessary for trafficking or formation of channel heterotetramers, including 
Kv11.1-1A and Kv11.1-3.1 heterotetramers, a partial or mutated PAS domain leads to an instable 
PAS structure and subsequent trafficking deficiency.145 Molecular rescue of these defects would 
facilitate efforts to create such a screening platform, and many examples of possible rescue 
techniques have been reported and characterized.193,197-202 Nevertheless, no successful method of 
rescuing Kv11.1-3.1 trafficking has been reported to date. 
 Efforts were taken to describe the extent of expression or trafficking defects while 
simultaneously applying methods to attempt rescue, compatible with HTS assay design. Here it is 
demonstrated that Kv11.1-3.1 shows poor steady-state expression, low channel activity, and 
trafficking deficits. Pharmacological agents may be used to rescue these phenotypes via blockade 
of proteasomal activity. Utilizing this technique, an improved channel assay signal amenable to 
HTS is possible. 
 
Materials and Methods 
 
Molecular Biology 
 Mammalian promoter constructs for the expression of C-terminally hemagglutinin (HA) tagged 
Kv11.1-3.1 or Kv11.1-1A were generated from KCNH2 and KCNH2-3.1 containing pcDNA 
3.1(+) (ampicillin-resistant) mammalian expression vectors, generously donated by Jingshan 
Chen at the National Institute for Mental Health (See Appendix for all primer sequences). One 
Shot® TOP10 chemically competent E. Coli cells were thawed on ice for 15 minutes prior to 
inoculation with vector. Inoculated cells were incubated on ice for 30 minutes and then placed in 
a 42⁰C water bath for heat shock transformation. Cells were incubated an additional 5 minutes on 
ice. Super optimal broth with catabolite repression (SOC media) was added and the cells in media 
were incubated at 37⁰C and agitated at 300 RPM in a shaking incubator for 1 hour. Cells in SOC 
media were then spread on Luria-Bertani (LB) agar plates containing 100 µg/mL ampicillin and 
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incubated at 37⁰C for 16 hours. Successfully transformed bacterial colonies were picked and 
grown in LB media containing 100 µg/mL ampicillin for 16 hours. Plasmid DNA was isolated 
and purified via Qiagen MAXI® kit per the manufacturer’s instructions. DNA purity and 
concentration was analyzed via Nanodrop 2000®. Plasmid DNA was diluted and used as 
template DNA for polymerase chain reaction (PCR) in order to extend transcripts with HA tag 
and appropriate endonuclease restriction sites. PCR was performed using the Qiagen LR PCR® 
kit per the manufacturer’s instructions with annealing temperatures based on the appropriate Tm 
calculated for each pair of primers. PCR products were analyzed and purified via agarose gel 
electrophoresis, visualized under UV light, and recovered using Qiagen gel purification kit per 
the manufacturer’s instructions. Purified products and desired expression vector, PiggyBac® 
pHULK® IRES-Serrano RFP® (including kanamycin and puromycin resistance cassettes), were 
digested with appropriate restriction enzymes for 2 hours at 37⁰C. Reaction mixtures were 
purified using the Qiagen PCR Purification® kit per the manufacturer’s instructions. Purified 
digested expression cassettes and expression vectors were ligated using New England Biolabs® 
T4 ligase per the manufacturer’s instructions. Ligation reaction mixture was inoculated into 
TOP10 cells and transformed as described. Transformed colonies were selected and analyzed for 
successful cloning as described. Cloning was validated via bi-directional Sanger Sequencing at 
the Johns Hopkins Sequencing Core. Validated clones were grown for MAXI® prep as described 
and the resulting purified DNA was used for transfection.     
 Stable cell lines expressing either Kv11.1-3.1 or Kv11.1-1A were engineered using parental 
Human Embryonic Kidney 293 (HEK 293) cells. Cells were thawed from frozen stocks stored in 
liquid nitrogen via rapid warming in a 37⁰C water bath and then diluted in Glutamax® 
Dulbecco’s modified Eagle’s Medium/Ham’s F-12 (DMEM/F12) supplemented with 100 U/mL   
Non-essential amino acids, 1x Penicillin/Streptomycin, and 10% fetal bovine serum. Media was 
removed by pelleting cells via centrifugation at 1000 g for 5 minutes and then aspirating the 
supernatant. Cells were resuspended in Glutamax media (vide supra) and plated in T75 vented 
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cell culture flasks. Cells were grown at 37⁰C under 5% CO2 to 80% confluency over a period of 
1-2 days. Media was removed by aspiration and dissociated from the flask using Tryple E 
Express dissociation reagent and incubation for 5 minutes at 37⁰C. Dissociated cells were 
resuspended in Glutamax media and the media was removed as described. Cells were plated in 6 
well plates for transfection and T75 flasks for line maintenance. Cells in the 6 well dish were 
transfected using the engineered plasmids and Lipofectamine 3000® per the manufacturer’s 
instructions. After 48 hours, cellular media was removed and replaced with Glutamax media 
containing 1 µg/mL puromycin. Single cells were selected by flow cytometry for maximum red 
fluorescence and plated into 96 well plates. Cells were cultured until clonal lines were established. 
Expression was verified by western blot and whole-cell patch clamp (vide infra). Scaled-up 
colonies were maintained in media containing 1µg/mL puromycin. 
 For stable cell line pharmacological trafficking treatments, drugs were dissolved in DMSO, and 
added to media (without puromycin) at DMSO final concentrations <0.2%. Cells were incubated 
in drug-containing media for 16-20 hours prior to assays.  
 
Electrophysiology 
HEK 293 cells stably expressing hERG channels were dissociated and plated onto PDL-coated 
glass coverslips in fresh puromycin-free media. Glass patch pipette electrodes were pulled using a 
PC-10® two-stage vertical puller. Average pipette resistance was between 2-3.5MΩ when filled 
with an internal solution containing: 120mM potassium gluconate, 5mM EGTA, 10mM HEPES, 
20mM KCl, 1.5mM Mg-ATP, at pH 7.3 with KOH. Plated cells were immersed in a perfused 
extracellular solution bath containing: 1mM MgCl2, 1mM CaCl2, 10mM HEPES, 12.5mM 
Glucose, 5mM KCl, 130mM NaCl, 0.1% dimethyl sulfoxide (DMSO), at pH 7.4 with NaOH. 
Liquid junction potential for these solutions was calculated to be -15mV, which was not corrected 
for in experiments. Cells were voltage clamped in whole cell mode using an Axopatch® 200B 
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amplifier. Current signal was digitized at 5 kHz and filtered at 10 kHz and stored on an IBM-
compatible PC interfaced with a NI USB-6221 analog-digital converter.  
 
SDS-PAGE electrophoresis and Western Blot 
 Cells were washed with ice-cold PBS, harvested in ice-cold PBS via scraping, and pelleted by 
centrifugation at 500 g for 5 minutes. Cell pellets were resuspended with 
Radioimmunoprecipitation assay (RIPA) buffer supplemented with 1x protease inhibitor and 
rotated at 4⁰C for 1 hour. Lysates were cleared by centrifugation at 16,000 g for 10 minutes and 
supernatants were analyzed for total protein concentration using a BCA kit per the manufacturer’s 
instructions. 30 µg of total protein lysate was taken from each sample and fractionated on a 4-12% 
gradient Novex® Bis-Tris Bolt® SDS-PAGE gel via electrophoresis (185 V, 1 hour). Proteins 
were transferred onto 0.45 µm nitrocellulose membranes and incubated for 1hr in Odyssey® PBS 
blocking buffer. Membranes were probed with anti-HA (1:5,000) and anti-NaK-ATPase (1:2,500) 
primary antibodies in Odyssey® PBS blocking buffer overnight at 4⁰C. Anti-HA and anti-NaK-
ATPase signals were detected using IRdye 800 donkey anti-rabbit (1:20,000) and IRdye 680 
donkey anti-mouse (1:20,000), respectively. The Li-Cor Odyssey® imaging system and software 
was used for antibody detection and quantification. 
 
Co-immunoprecipitation 
 Dynabeads Protein G® were prepared according to the manufacturer’s instructions and incubated 
with HA.11 anti-HA antibody for 30 minutes and then fixed with BS3 crosslinking reagent to 
prevent antibody dissociation, per the manufacturer’s instructions. Equal amounts of cell lysates 
from stably expressing Kv11.1 cell lines were prepared as before and then incubated with the 
prepared beads overnight at 4⁰C. Beads were washed and proteins were eluted per the 
manufacturer’s instructions and visualized via SDS-PAGE. Membranes were probed with the 
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 Stable HEK 293 cell lines expressing either the full-length (1A) or deletion Kv11.1 (3.1) channel 
variant were plated onto 24 well ibiTreat® plates and grown until 80-90% confluent. For sub-
cellular co-localization studies, cells were fixed with 4% paraformaldehyde in PBS for 15 
minutes. Cells were simultaneously permeabilized, blocked, and quenched for background 
fluorescence by incubation in a PBS solution containing 0.1% Triton X-100, 10% normal goat 
serum, and 0.75% glycine for 15 minutes. Cells were probed with primary antibodies: anti-
extracellular loop hERG (1:1000), anti-calnexin (1:1000), anti-58K Golgi protein (1:200), anti-
20s proteasome β1 (1:200).  For cell-surface labeling, fixation time was reduced to 10 minutes 
and paraformaldehyde concentration was reduced to 2% to reduce permeabilization.  Cell surface 
labeling with anti-hERG antibody was performed as described above.  Cell images were captured 





 All voltages protocols used are illustrated on or above the relevant panel. For manual patch, to 
induce both steady-state and tail currents, cells were held at a potential of -80 mV, depolarized to 
0 mV for 5 s and then hyperpolarized to -120 mV for 3 s. To measure rates of deactivation, cells 
were first depolarized to 20 mV for 500 ms to completely activate the channels. Cells were then 
repolarized to voltages in the range −60 to −130 mV for 5 s and traces were fitted to 




FluxOR® Thallium Flux Assay 
 Stably Kv11.1 channel expressing HEK 293 cells grown to 90% confluency were then plated 
onto PDL coated 384 well plates and allowed to grow 16-20 hours at 37⁰C with (Kv11.1-3.1) or 
without (Kv11.1-1A) 10 nM bortezomib. FluxOR® loading buffer supplemented with 10mM Red 
Dye #40 was added to each well and incubated for 45 minutes. Compounds were diluted in assay 
buffer containing 2.5 mM ouabain and then added and incubated for 10 minutes. Stimulation 
buffer was added to plates in a FDSS7000 kinetic plate reader while channel activity was 
monitored. Channel activity was analyzed using the Hamamatsu® FDSS software and 
Dotmatics®.  
 
Data Analysis and Statistics  
 Electrophysisology data analysis was performed using Axograph X®. All data is presented as 
mean ± SEM unless specified. Unpaired T-tests, ANOVA, and subsequent Bonferroni corrections 
were completed using Graphpad Prism®. Microscopy data was analyzed with linear mixed 
models with fixed effects for the treatment variables with a random intercept by replicate/well – 





Kv11.1-3.1 is a poor expressing, trafficking deficient hERG channel 
 The HEK 293 cell overexpression model was used to determine steady-state expression levels, 
trafficking efficiency, and activity of Kv11.1-3.1, via electrophysiology, immunoblotting, and 
immunocytochemistry. With the intention of controlling for channel transcription and transfection 
efficiency, mRNA levels were evaluated by qPCR. Transcription levels from selected Kv11.1-1A 
and Kv11.1-3.1 cell lines did not vary significantly, although Kv11.1-3.1 displayed a non-
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significant increase relative to Kv11.1-1A transcription (P=0.058) (Figure 2.1b iii). Subsequent 
quantified data was not normalized to transcription levels due to these findings. 
 Channel activity was characterized via electrophysiology using whole-cell voltage clamp to 
determine efficacy in downstream HTS assays. Utilizing a test pulse protocol, by holding cells at 
-80 mV followed by depolarization at 0 mV and hyperpolarization at -120 mV (Figure 2.1c ii), 
differences in tail current deactivation between Kv11.1-1A and Kv11.1-3.1 were evident (Figure 
2.1c i).  Consistent peak tail current expression over 1 nA was considered acceptable for drug 
screening. The Kv11.1-1A line was quite robust in yielding large tail currents (>4 nA) as well as 
exhibiting a high fidelity of expression between cells. However, the Kv11.1-3.1 cell line did not 
produce a robust signal response in every cell, and it was uncommon to identify cells with tail 
current peaks over 1 nA. Cell membrane capacitance normalized peak tail currents from Kv11.1-
3.1 expressing cells (22.66 ± 6.108 pA/pF, n=8) were significantly lower (P=0.0072) than 
currents recorded from Kv11.1-1A expressing cells (381.6 ± 95.82 pA/pF, n=8) (Figure 2.1c iii). 
Knowing that the expression rate and magnitude are critical for HTS methods192, it was concluded 
that even the best expressing Kv11.1-3.1 lines were insufficient for a drug discovery platform. 
Before investigating the nature of these deficits and approaches to improve channel activity, it 
was necessary to characterize expression and trafficking levels to better understand the cause of 
low channel activity. 
 Western blot analysis was used to quantify expression and trafficking, as reported by previous 
groups.152 HEK 293 cells overexpressing Kv11.1 show distinct bands via western blot: the mature 
fully glycosylated (FG) band and immature core glycosylated (CG) band. The core glycosylated 
band for Kv11.1-1A and Kv11.1-3.1 appears at 135kD and 125kD, respectively, while the FG 
band for each is approximately 20 kDa higher (Figure 2.1b i). These bands have been used 
previously as a heuristic diagnostic of channel trafficking 144,152,197,199,202,203, as the lower band is 
representative of channel present in the ER, being subject to only one glycosylation event, while 
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Figure 2.1. Kv11.1-3.1 is an N-terminally truncated hERG channel with trafficking, 
expression, and activity deficiencies. a, Illustrative examples of Kv11.1-1A (i) and Kv11.1-
3.1(ii) channel structure. Full length Kv11.1 channels contain N-terminal PAS domain and 
amphipathic helix N-cap, suggested to interact with each other and a C-terminal cyclic nucleotide 
biding domain. Kv11.1-3.1, being absent of a full PAS domain, likely presents an unstably folded 
N-terminal motif. b, Sample Western blot (i) of whole cell lysates from stably transfected HEK 
293 cells expressing recombinant HA-tagged Kv11.1-1A, Kv11.1-3.1, or Kv11.1-3.1 after 20 
hour incubation at 28⁰C (ΔT). Lysates were probed with anti-HA and anti-NaK ATPase primary 
antibodies subsequently incubated with fluorescent IR dyes for quantitative detection. Ladder 
markers indicated with respective sizes in kDa. Arrows indicate respective FG and CG bands 
representative of mature fully glycosylated and immature core glycosylated channel populations. 
Neither 3.1 nor cold-incubated 3.1 show obvious FG band expression, suggesting the 3.1 
trafficking phenotype is heat-insensitive. (ii) Summary quantification of trafficking efficiency 
(FG/Total hERG, n=3) and relative expression differences (Total hERG/NaK ATPase normalized 
to 1A expression, n=3) of 1A and 3.1 channels. 3.1 showed significant decreases in both 
trafficking and steady-state expression. Note that while no FG signal is visible for Kv11.1-3.1, 
there is a photon count present above true background.  (iii) Kv11.1-3.1 expressing cells show a 
non-significant increase in total hERG channel transcription compared to Kv11.1-1A expressing 
cells via qPCR( n=3). c, (i) Example whole-cell deactivation tail current voltage clamp traces 
from HEK 293 cells expressing 1A or 3.1 channels. (ii) Currents were recorded by holding cells 
at -80 mV, activating channels with a voltage step to 0 mV for 5s, followed by a hyperpolarizing 
step to -120 mV  to induce tail currents. 3.1 displays rapid deactivation compared to 1A. (iii) Peak 
tail currents from 1A and 3.1 traces were normalized to cell capacitance (pA/pF, n=8) and 
analyzed. 3.1 shows significantly reduce average peak tail current relative to 1A. All bar graph 






 the FG band is indicative of successfully trafficked channel being glycosylated again in the 
Golgi.128  
 The overall steady-state expression was determined by summing the total photon signal from 
both FG and CG bands normalized by the NaK ATPase loading control count. It was discovered 
that basal Kv11.1-3.1 expression was only 15±2 % (P=0.0008) of that to Kv11.1-1A levels on the 
same blot (Figure 2.1b ii). Furthermore, by calculating trafficking expression as a function of FG 
photon count normalized by total hERG photon count (FG+CG) it was found that Kv11.1-1A and 
Kv11.1-3.1 cells exhibited a significantly different (P=0.0002) trafficking efficiency of 32 ±2 % 
(n=3) and 8±1% (n=3) respectively (Figure 2.1b ii).   
 To establish the sub-cellular localization of Kv11.1-1A and -3.1, we performed co-localization 
studies using antibodies against Kv11.1 and control sub-cellular markers (Figure 2.2). Kv11.1 
signal was measured in the nucleus and cytoplasm using DAPI as a differential counterstain for 
the nucleus and cytoplasm (Figure 2.2a). To normalize the anti-Kv11.1 antibody fluorescence in 
each cell, we also measured signal from the red fluorescent protein (RFP) that is expressed from 
an internal ribosome entry site (IRES). Characteristic fluorescence micrographs demonstrate the 
localization of both transgenes to the cytoplasm (Figure 2.2b). Total Kv11.1 fluorescence was 
measured in domains defined by the expression of the control organelle markers calnexin (ER), 
58k (Golgi), and alpha 5 (proteasome) (Figures 2.2c-d). The fluorescence signal from Kv11.1-
3.1 was significantly lower in all measured domains.  
 
Kv11.1-3.1 expression and trafficking is rescued through proteasome inhibition 
 It has been demonstrated that many Kv11.1-1A LQT2 mutant trafficking defects are responsive 
to overnight low temperature incubation, while some are completely unaffected.201 Upon 
incubation of Kv11.1-3.1 expressing HEK 293 cells at 28⁰C for 16-20 hours, no FG band rescue 




Figure 2.2. Single cell measurements of Kv11.1-1A and Kv11.1-3.1 show reduced expression 
across sub-cellular compartments. a, Total Kv11.1-1A and Kv11.1-3.1 signal (RFU) was 
measured in each cell and normalized to the RFP signal from the same cells.  Note the reduced 
signal in 3.1 from both nucleus and cytoplasm (n=3 unique experiments).  b, Representative 
fluorescence micrographs show both fluorescence signal and overlay after sub-cellular image 
segmentation. c, RFP-normalized signal from indicated sub-cellular compartments (n=3 unique 
experiments). d, Fluorescence micrographs demonstrate localized signal from Kv11.1 and the 
organelle-specific masks used for sub-cellular localization. Colocalization and segmentation data 
used is from same experiment in Figure 2.5. Scale bars=100µm.  All bar graph data presented as 









responsive to cold incubation, pharmacological rescue agents were then investigated using the 
same phenotypic Western blot screening.  
 A library of small molecules, that were either reported in the literature, or that were preliminarily 
identified for hERG activity, ERAD/UPR modulation, protease activity, or activity in other 
germane processes, was created147,199,204-209. Initially, it was found that the 26s proteasome 
inhibitor Mg132 210 boosted CG expression levels, but was too cytotoxic for reproducible use 
(data not reported). Likewise, it was shown that the calpain/cathepsin/proteasome inhibitor N-[N-
(N-acetyl-L-leucyl)-L-leucyl]-L-norlecucine (ALLN) 198,211 greatly increased Kv11.1-3.1 CG 
expression. (Figure 2.3a) Furthermore, ALLN was the only compound to show the clear presence 
of a Kv11.1-3.1 FG band after treatment (Figure 2.3a). Upon quantitative western analysis, 
optimal concentrations of ALLN rescued trafficking efficiency (25 ± 3%, n=3, P=0.0006) to 
similar levels seen in untreated Kv11.1-1A cells (Figure 2.3b i) and increased overall channel 
expression by over 4-fold (Figure 2.3b ii, P=0.001). Whole-cell voltage clamp test pulses evoked 
larger peak tail currents for ALLN treated cells expressing Kv11.1-3.1, than for untreated controls 
(Figure 2.3c i). Cell membrane capacitance normalized tail current peaks were found to be 
significantly greater (P=0.0472) in the ALLN treated cell groups (45.02 ± 5.079 pA/pF, n=9) 
compared to Kv11.1-3.1 controls (18.65 ± 4.714 pA/pF, n=8) (Figure 2.3c ii). To understand if 
this effect was selective for the Kv11.1-3.1 specific deficiencies, Kv11.1-1A expressing cells 
were treated with ALLN in a similar manner. Neither overall Kv11.1-1A expression nor 
trafficking efficiency was significantly altered with ALLN treatment (Figure 2.3a-b). 
 Although these findings supported ALLN as a good candidate for a rescue agent, ALLN contains 
a reactive aldehyde species and exhibits polypharmacology across multiple proteases.200,212 
Consequently it was necessary to investigate the mechanism of rescue. By comparing τ for 
deactivation of ALLN treated Kv11.1-3.1 expressing cells and controls (Figure 2.4e), it was 
demonstrated that no significant difference was seen in the primary Kv11.1-3.1/Kv11.1-1A-





Figure 2.3. Kv11.1-3.1 expression, trafficking, and peak tail currents are significantly 
increased via pharmacological rescue with ALLN. a, Example Western blot analysis of cells 
expressing 1A or 3.1 treated with the calpain/lysosomal cathepsin/proteasome inhibitor ALLN. 
ALLN treatment of 3.1 expressing cells resulted in presence of the FG band and increased CG 
band intensity while only increasing 1A CG expression. b, Quantitation summary of Western 
analysis shows significant increases of i) 3.1 trafficking and ii) total hERG expression upon 
ALLN treatment (n=3). No significant effects were seen in 1A expressing cells. c, i) 
Representative whole-cell voltage clamp tail current traces for ALLN treated 3.1 cells. ii) Peak 
tail currents were normalized to cell capacitance (n=8) and analyzed. ALLN treatment was found 
to significantly increase normalized peak tail currents compared to untreated cells (*P=<0.05). 
All bar graph data presented as mean ± SEM (*P=<0.05, **P=<0.01, ***P=<0.001). 
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modification. In order to deconvolute the ALLN polypharmacology for principle 
pharmacodynamic contributions, Kv11.1-3.1 expressing cells were treated with small molecules 
selective for cathepsins B,L, calpains I,II and the 26s proteasome, the multiple ALLN targets. The 
calpain I/II inhibitor PD 150606, the cathepsin B inhibitor CA 078, the cathepsin L inhibitor SID 
26681509, and the 26s proteasome inhibitor bortezomib were chosen.213-216 It was also anticipated 
that the rescue activity of ALLN might arise from the specific polypharmacological profile, so 
various cocktails of these inhibitors were formulated for screening. Western blot analysis from 
these treated cells (Figure 2.4a) yielded that only bortezomib was effective, hence 26s 
proteasome inhibition was responsible for Kv11.1-3.1 expression and trafficking increases.  
 Bortezomib was titrated for optimal rescue attributes and identical concentrations were tested in 
the Kv11.1-1A cell line (Figure 2.4b). At 10nM, bortezomib was found to rescue Kv11.1-3.1 
channel trafficking (25 ± 2%, n=4, P=<0.0001) (Figure 2.4c i), increase overall Kv11.1-3.1 
channel expression by an average of 6 fold (Figure 2.4c ii, P=<0.0001), and increase peak tail 
currents (Figure 2.4d i). The increase in cell membrane capacitance normalized peak tail currents 
(75.93 ± 11.84 pA/pF, n=8) was found to be greater than that of untreated Kv11.1-3.1 expressing 
cells (Figure 2.4d ii, P=<0.0001). Bortezomib treatment had no effect on Kv11.1-3.1 
deactivation rate kinetics (Figure 2.4e).   
 Quantitative immunofluorescence of Kv11.1 1A and Kv11.1-3.1 supports the conclusion from 
electrophysiological studies that low Kv11.1-3.1 levels are a consequence of a proteasomal 
mechanism (Figure 2.5).  Although modest elevation of Kv11.1 1A was detected when cultured 
in the presence of ALLN and bortezomib, a nearly 3-fold elevation of steady-state protein level 
was detected in the Kv11.1-3.1 variant when treated with ALLN or bortezomib (Figure 2.5a). 
When analyzed at subcellular segmentation and colocalization domains, both ALLN and 
bortezomib significantly increased Kv11.1-3.1 expression in the cytoplasm and nuclear regions 
along with the  
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Figure 2.4. Proteasome inhibition is sufficient for Kv11.1-3.1  rescue via bortezomib. a, 
Example blot of 3.1 expressing cells treated with either selective calpain I/II inhibitor PD 150606,  
lysosomal cathepsin B/ L inhibitors CA 074/SID 26681509, 26s proteasome inhibitor bortezomib, 
or various cocktails in order to determine ALLN mechanism of rescue. Only samples treated with 
bortezomib, or a cocktail consisting thereof, resulted in the display of a FG band. b, Example blot 
of cells expressing 1A or 3.1 treated with bortezomib. Treatment of 3.1 expressing cells with 
bortezomib results in presence of the FG band and increased CG band intensity while only 
increasing 1A CG expression. c, Quantitation summary of Western analysis shows significant 
increases of i) 3.1 trafficking and ii) total hERG expression upon bortezomib treatment(n=3). d, i) 
Representative whole-cell voltage clamp tail current traces for bortezomib treated 3.1 cells. ii) 
Peak tail currents were normalized to cell capacitance (n=8) and analyzed. Bortezomib treatment 
was found to significantly increase normalized peak tail currents compared to untreated cells 
(****P=<0.0001). Note data for untreated 3.1 peak tail currents is from the same experiments in 
Figure 2.3c ii.  e, Pharmacological rescue conditions were tested for alterations to channel 
kinetics according to deactivation rate voltage protocol. i) Extrapolated τdeact values for 
pharmacologically treated cells were not shown to be significantly different from those of 
controls, thus rescue compounds had no effect on Kv11.1-3.1 deactivation rates (n=3). All bar 







Figure 2.5. Proteasome inhibitor treated cells show Kv11.1-3.1 rescue across sub-cellular 
compartments and cell surface.  a, RFP-normalized fluorescence of Kv11.1 1A and 3.1.  Note 
the differential elevation of 3.1 compared to 1A after the same treatments (n=3). b, Scatter plot of 
RFP vs surface Kv11.1 in single cells, n > 3000 measurements per condition (n=3 unique 
experiments).  m = slope of the linear regression (solid line). The dotted lines have slope m=1 for 
reference. c, Immunofluorescence micrographs of representative fields showing specific surface 








ER and Golgi. However, the increases in Kv11.1-3.1 proteasome domain expression were not 
found to be significant.  Increased electrophysiological activity of Kv11.1-3.1 in the presence of 
bortezomib should involve increased localization of this channel to the cell surface.  Using an 
antibody that recognizes an extra-cellular loop found in both Kv11.1-1A and Kv11.1-3.1, we 
performed immunocytochemistry with a brief fixation protocol that maintains the plasma 
membrane integrity (Figure 2.5b).  To normalize the anti-Kv11.1 antibody fluorescence in each 
cell, we also measured signal from the red fluorescent protein (RFP) that is expressed from an 
internal ribosome entry site (IRES).  Thus, the mRNAs for both Kv11.1 and RFP are regulated by 
a single common promoter, while the relative stability of each protein is a consequence of post-
transcriptional mechanisms.  The ratio of Kv11.1-1A/RFP (m=0.34) is minimally altered by 
ALLN (m=0.36, P=0.029) and bortezomib (m=.40, n.s.) as shown by the similar linear regression 
slopes (Figure 2.5b).  In contrast, bortezomib and ALLN increase this ratio (b=0.39) by a factor 
of 2 in the Kv11.1-3.1 variant (m=0.75, P=.028 and m=0.83, P=<0.0001 respectively) (Figure 
2.5b), demonstrating specific elevation of the Kv11.1-3.1 variant surface abundance with these 
small molecules.  Representative fluorescence micrographs of Kv11.1 3.1 alone and in the 
presence of ALLN demonstrate the dramatic specific elevation of Kv11.1 3.1 (Figure 2.5c).  
Note the increase in Kv11.1 signal without change of RFP in the Kv11.1-3.1 variant only in the 
presence of ALLN or bortezomib.  These data provide the third independent measurement of 
Kv11.1 3.1 demonstrating increased protein stability in the presence of proteasome inhibitors.  
 While it is known Kv11.1-1A channels are ubiquitinylated in HEK 293 cells prior to proteasome 
degradation 217, no such mechanism has been shown for Kv11.1-3.1 channels, critical in exploring 
potential proteasome-dependent regulation of Kv11.1-3.1 channels. Immunoprecipitation of 
Kv11.1-1A and Kv11.1-3.1 channels was performed with and without pharmacological recue 
conditions with bortezomib (Figure 2.6). Immunoprecipitated channels lacked lysate loading 
control bands, and mouse IGG only samples (data not shown) did not yield signal, suggesting the 


















Figure 2.6. Kv11.1-1A and Kv11.1-3.1 show different channel ubiqunylation changes in 
response to bortezomib. HA tagged hERG channels were immunoprecipated from stably 
expressing hERG cell lysates that had been incubated with bortezomib or DMSO for 16 hours. 
Cell lysates and IP elutions were probed for HA tag, NaK ATPase, and ubiquitin. Cell lysates 
show increases in total ubiquitin with bortezomib treatment and both 1A and 3.1 channels show 
poly-ubiquitinylation. Immunoprecipitated 1A channels show increase in ubiquitnylation 
accumulation in bortezomib treatments. Immunoprecipitated 3.1 channels from bortezomib 
treated cells show less accumulation than DMSO incubated cells.  
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channels showed similar hERG signals as before, however the CG/FG band locates were slighty 
shifted up, likely due to different loading buffer conditions from the Protein A bead dissociation. 
Cell lysates from the respective cell lines showed increases in ubiquitin signal with bortezomib 
treatment. Immunoprecipitated 1A channels showed ubiquitinylation and accumulation of 
ubiquitin signal upon bortezomib treatment. Immunoprecipitated Kv11.1-3.1 channels showed 
ubiquitinylation, however, a decrease in ubiquitin signal upon bortezomib treatment.  
 
Rescued Kv11.1-3.1 activity is suitable for High Throughput Screening 
 To determine if these rescue strategies could be successfully employed for a HTS assay, Kv11.1-
3.1 expressing cells were treated as in the Western assays, and plated in multi-well plates in 
preparation for a potassium channel flux assay based on a thallium-sensitive dye.125 ALLN and 
bortezomib treated cells both yielded significant signal improvement compared to untreated cells 
in the 384 well thallium flux assay with low variations between wells, both showing roughly 4 
fold signal to background ratios (Figure 2.7a). Due to its lower effective concentration and 
repeated superiority to ALLN in assays for expression and trafficking, bortezomib was chosen as 
the rescue agent in subsequent HTS assays.  
 Using bortezomib treated Kv11.1-3.1 and untreated Kv11.1-1A cells, multiple assay plates were 
run in the thallium flux assay with the known Kv11.1 inhibitor E4031 and DMSO as controls. 
Repeated assay plates generated Z’ scores of 0.811±0.07 for Kv11.1-1A cells without proteasome 
inhibitor and 0.797±0.02 for treated Kv11.1-3.1 cells (Figure 2.7a).  Dose-response curves were 
generated (Figure 2.7c) for E4031 inhibition, and a known hERG activator, ML-T531.209 
Additionally, these small molecules were titrated with treated Kv11.1-3.1 and Kv11.1-1A cells in 
the same voltage-clamp assay used to determine capacitance normalized tail current (Figure 2.7b) 
for assay comparison. E4031 had uniformly 3-fold less potency against both channels (Figure 
2.7d) in the thallium flux assay as compared to voltage clamp, showing no significant selectivity 
between channels. EC50 values for ML-T531 were similarly identical for Kv11.1-1A and Kv11.1-
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3.1 in these assays, near 4µM. However, a higher maximum potentiation effect was seen for 
Kv11.1-3.1 as compared to Kv11.1-1A. EC50 values were also conserved across assay platforms, 




Figure 2.7. Bortezomib treatment of Kv11.1-3.1 expressing cells produces sufficient currents 
for dose-response analysis of hERG inhibitors and activators via whole cell voltage clamp 
and high throughput fluorescence methods. a, 3.1 expressing cells were treated with ALLN or 
bortezomib as before in 384 well assay plates. Plates were incubated the next day with assay 
loading buffer for 45 minutes, and then incubated with either E4031 or DMSO for 5 minutes prior 
to addition of stimulation buffer and subsequent signal detection. Comparison of 
pharmacologically treated 3.1 expressing cells and controls shows that both ALLN and 
bortezomib tremendously increase signal to background window in the thallium flux assay (n=16). 
Z’ scores for the thallium flux assay with either 1A cells or 3.1 cells treated with bortezomib are 
well above the 0.5 threshold across multiple trials (n=3). b, Dose-response of peak tail currents to 
either E4031 (n=4) or ML-T531 (1A n=3, 3.1 n=6) titration in whole-cell voltage clamp of cells 
expressing either 1A or 3.1 treated with bortezomib. c, Dose-response of peak tail currents to 
either E4031 (n=4) or ML-T531 (1A n=3, 3.1 n=6) titration in thallium flux assay of cells 
expressing either 1A or 3.1 treated with bortezomib. d, Table summary of compound potencies 
and activator potentiation data. E4031 potencies decrease in thallium flux assay compared to 
voltage-clamp by less than 3 fold. ML-T531 exhibits higher max potentiation in 3.1 channels than 










 In this study it was confirmed that Kv11.1-3.1 is a poorly expressed channel that displays 
impaired trafficking and activity (Figure 2.1). This data reflects general observations made 
concerning Kv11.1-3.1 expression in HEK cells via Western analysis 145,187; however, this is the 
first time these characteristics have been quantified, analyzed, and also reflected in fluorescent 
microscopy (Figure 2.2) to our knowledge. Of particular interest are the general subcellular 
localization analyses; these demonstrate Kv11.1-1A is expressed over 6 fold higher in the Golgi, 
2 fold higher in the ER, and 2 fold higher in the proteasome domains, as compared to Kv11.1-3.1. 
While 1A expression in the Golgi and ER is similar, there is a much greater ratio of Kv11.1-3.1 in 
the ER/Golgi, suggesting a differential kinetic distribution and thus supporting the trafficking 
hypothesis. Using the same methods, it was found that inhibition of proteasome activity increased 
steady-state expression, plasma membrane trafficking, and subsequent peak current of Kv11.1-3.1. 
(Figures 2.3-2.5) These findings were applied to the fluorescent 384 well plate thallium flux 
assay for potassium channel activation, and it was found that rescue via proteasome inhibition 
resulted in a robust response, amenable for HTS and subsequent drug discovery studies. In 
general, the discoveries outlined in this report suggest two principal implications: the role of 
ERAD and UPR in Kv11.1-3.1 regulation and a potential translational component. 
 Proteasome involvement is known in hERG trafficking and degradation 128,202, but is not often 
labeled as the key factor in these pathways. Nonspecific ALLN treatment has previously shown 
rescue of general hERG 1A expression when coexpressed heterogeneously with a dominant 
negative LQT2 mutant, although the effects on trafficking are not clear.211 Although proteasomal 
inhibition via lactacystin and Mg132 treatment has been shown previously to increase hERG 
expression for some LQT2 mutants 202, trafficking was unable to be rescued suggesting a different 
limiting factor. The majority of hERG trafficking studies target LQT2 clinically relevant 
missense mutations and PAS truncations.128 These cause channel retention in different 
compartments of the endoplasmic reticulum 147, which may vary on the mutation despite similar 
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CG channel expression. Related studies include the more severely truncated variant Kv11.1-1B, 
which results in analogous observations due to the expression of RXR retention motifs.155 
Successful rescue strategies for trafficking deficient Kv11.1-1 channels include pharmacological 
chaperones, incubation at reduced temperature, and expression of heterotetramers with WT 
Kv11.1-1A. These rescue techniques either assist in stabilizing channels or disrupt chaperone 
mediated quality control mechanisms. 128,155,197,199-201 In contrast, we hypothesize that Kv11.1-3-
1’s unstably folded N-terminal region, caused by alternative transcription, results in a unique 
kinetic distribution amongst ER quality control check points and possibly different chaperone 
interactions. Due to insensitivity to other rescue strategies (Figure 2.1), the robust response from 
bortezomib and ALLN (Figures 2.3-2.5), and lack of specific 3.1 ubiquitinylation upon 
proteasome inhibition (Figure 2.6), it is possible that Kv11.1-3.1 channels are more rapidly 
degraded by the proteasome than other defective hERG channels. Therefore, it may be improper 
to describe Kv11.1-3.1 as a truly trafficking deficient channel. In fact, there may be utility in 
comparing Kv11.1-3.1 to the previously reported Δ2-135 truncated hERG channel145. Despite 
absence of the PAS domain and N-cap, Δ2-135 has increased trafficking and similar stability 
compared to Kv11.1-1A. In a sense, Kv11.1-3.1 may be seen as analogous to Δ2-135 with the 
addition of a small misfolded region causing immediate targeting to the proteasome. It may also 
be worthwhile to examine LQT2 mutants, resistant to typical methods of rescue, under 
proteasome inhibition in HEK cells.  
 Continued exploration of Kv11.1-3.1’s trafficking mechanisms to the proteasome in brain and 
other cell lines may be of interest to discover new therapeutic targets that increase Kv11.1-3.1 
retention and degradation in patients with abnormally high Kv11.1-3.1 expression. Because 
Kv11.1-3.1 is expressed in healthy controls 176, increased Kv11.1-3.1 expression alone is not 
sufficient for a disease state. Considering previous work that has shown UPR to be down 
regulated in some groups of schizophrenia patients 218,219, it may be of value to investigate the 
effect of these two possible risk factors. As this study suggests ERAD and UPR play a large role 
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in the expression and trafficking of Kv11.1-3.1, one may imagine a feed-forward effect in a 
down-regulated UPR patient. 
 In addition to basic channel regulation, these results provided insight into the abilities of using 
Kv11.1-3.1 for drug discovery. Through proteasome inhibition, the Kv11.1-3.1 signal was 
improved and resulted in gratifying enhancement of Z’ values comparable to Kv11.1-1A. The 
two tool compounds, E4031 and ML-T531, displayed fidelity between the voltage-clamp and 
fluorescent thallium flux assay (Figure 2.5d). Generally, IC50/EC50 values were consistent 
between assays, although the thallium flux yielded 3 fold lower potencies for E4031 in both 
Kv11.1-1A and Kv11.1-3.1 expressing cells. Nevertheless, thallium flux data is known to 
correlate well (albeit not perfectly) to voltage-clamp, and these results are consistent with 
previous studies comparing E4031 potencies between the two assays.125 
 A principal goal of this assay is to determine selectivity of molecules for the Kv11.1-3.1 channel 
in order to avoid future cardiac toxicity.  Neither the hERG inhibitor E4031 nor activator ML-
T531 showed selectivity between Kv11.1-1A and Kv11.1-3.1.  However, it was seen that ML-
T531 significantly potentiated Kv11.1-3.1 current more so than Kv11.1-1A. While it is unclear as 
to why this is observed, it should be noted that the EC50 between channels was essentially 
identical. Therefore, the differences in potentiation increase may be attributed to intrinsic 
differences amongst channel fluxes and it may be considered that even nonselective compounds 
have a small “built-in” selectivity for Kv11.1-3.1 as compared to Kv11.1-1A.  
 In this study vital infrastructure has been established to interrogate Kv11.1-3.1 as a drug 
discovery target for new schizophrenia therapeutics through simultaneously unveiling a novel 
mechanism for hERG channel trafficking deficiency via rapid proteasomal degradation. While 
efforts to establish a pipeline for this novel cognitive target are in preliminary stages, these 
findings present an opportunity to discover other interacting druggable targets and create the tools 





Preferential activity of atypical anti-psychotics for Kv11.1-3.1 
 
Introduction 
 Many antipsychotic agents have been shown to bind to Kv11.1 channels, resulting in associations 
with long QT risk and arrhythmic events causing sudden unexpected death and sudden cardiac 
death.172 However, some reports suggest that inhibition of hERG currents may also contribute to 
antipsychotic efficacy as these channels have been shown to play a role in various neurological 
signaling processes, including dopamine regulation. Indeed, antipsychotic-induced hERG 
blockage reduces post-stimulus inhibitory periods in action potential trains, increasing excitability. 
This increase in excitability creates a time-dependent inactivation of dopamine neuron activity 
(depolarization block) which has been observed in animal models and is thought to correlate with 
clinical efficacy.175 
 Studies exhibiting the different gating kinetics of Kv11.1-1A and Kv11.1-3.1 have implicated 
pathological dynamics in their relative contributions to the depolarization block hypothesis. Due 
to rapid deactivation kinetics found in Kv11.1-3.1, less current is accumulated during repeated 
depolarization pulses, which may produce faster, longer lasting trains of action potentials.187 
However it is unknown whether these rapid, long lasting trains of actions potentials result in 
similar depolarization block or increase basal dopaminergic activity, (as current studies would 
suggest the latter without any trials examining the former). If Kv11.1-3.1 does apply negative 
function, then selective inhibition may provide a therapeutic effect. 
 This hypothesis has been evaluated clinically (see Chapter 1), with preliminary evidence 
showing that risperidone is 2-fold selective against Kv11.1-3.l and is correlated to improve 
clinical outcomes with prescribed to poor metabolizing patients with KCNH2-3.1 up-regulating 
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risk alleles.189 Similar clinical effects have been reported for olanzapine, although it has shown to 
be non-selective between channel isoforms.189,220  
 While the study of risperidone was the first work to comparatively assay common antipsychotics 
on Kv11.1-3.1 activity, it was limited to only 6 agents.189 This limitation was likely due to the 
burden of manual patch low throughput. If one is to compare the differential effects of agents on 
both channel isoforms for linking marketed antipsychotic efficacy or drug discovery, a more 
efficient platform is needed. 
 In this study, we established a high-throughput electrophysiological assay that could drastically 
increase screening capabilities for the evaluation of novel agents and known antipsychotics. 
Using a small collection of 26 antipsychotic compounds, or other agents with reported 
antipsychotic/CNS activity, we sought to find any other selective behaviors and confirm previous 
results to validate a putative high throughput assay. 
 
Materials and Methods 
  
 Molecular biology 
 Bacmam virus was produced via PCR of C-terminally hemagglutinin (HA) tagged  Kv11.1-1A 
and Kv11.1-3.1 constructs for cloning (as described in Chapter II) into Gateway® donor vector 
pENTR 1A. Donor vector was used for reaction with Virapower BacMam Gateway® vector per 
the manufacturer’s instructions. After the completion of the Gateway recombination, DH5αBac 
chemically competent E.Coli cells were transformed with the Gateway product per the 
manufacturer’s instructions, resulting in a transposition reaction of the BacMam cassette into the 
bacmid. Insertion was verified via bi-direction bacmid sequencing of the target site. Bacmid was 
used to create filtered, high titer BacMam virus (2x108 virons/mL) at Kemp Bio® via SF-9 cell 
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transfection for host-mediated viral replication and amplification. 
  
FluxOR® Thallium Flux Assay 
 FluxOR assays were performed as described in ChapterII.  
 
Electrophysiology 
 HEK 293 cells were grown and maintained as described in Chapter II using Glutamax® 
Dulbecco’s modified Eagle’s Medium (DMEM) supplemented with 100 U/mL non-
essential amino acids, 1x Penicillin/Streptomycin, and 10% fetal bovine serum. Cells were 
dissociated and separated from media via addition of Tryple E Express® and centrifugation. Cells 
were resuspended in DMEM/F12 media containing 2% FBS at a concentration of 2 million 
cells/mL. Virus was added to cells at an MOI of 100:1 and gently rotated at room temperature in 
the dark for 4 hours in a centrifugal tube wrapped in aluminum foil. Virus and media was 
removed by centrifugation and cells were suspended in fully supplemented DMEM media 
containing a final concentration of 1X BacMam enhancer solution. Cells were plated onto PDL 
coated glass coverslips or 15 cm dishes at 15 million cells per dish and incubated at 37 ⁰C for 4 
hours. Media was removed by aspiration and replaced with fresh DMEM containing 10 nM 
bortezomib. Cells were manually patched using protocols as previously described in Chapter II. 
Dose response data was taken from steady-state currents. Automated patch-clamp experiments 
were performed using the population patch-clamp (PPC) mode of automated voltage clamp 
recording with IonWorks Quattro™. Briefly, compound effects on Kv11.1-1A and Kv11.1-3.1 
channels were tested with a one-step voltage protocol. Cells were dispensed into a 384-well 
population patch-clamp mode plate. After dispensing, seal resistance of cells was measured for 
each well and cells were perforated by incubation with 100 μg/mL amphotericin B. Activity of 
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hERG was then measured with the recording protocol as follows: cells were held at −70 mV, 
stepped down to −80 mV for 100 ms to estimate leak currents, and depolarized to −30 mV for 
100 ms to estimate non-hERG currents. Then cells were depolarized to +45 mV for 2 s followed 
by a hyperpolarization to −10 mV for 2 s. This series of pulses was applied to cells before and 
following an 8-min incubation of cells with test compounds or assay buffer. Positive (30 μM 
cisapride) and negative controls (external buffer with 0.02% [v/v] DMSO) were applied within 
each plate to evaluate the data quality. Only cells with a tail current amplitude bigger than 0.2 nA, 
a seal resistance >30 MOhms, and seal resistance drop rate lower than 25% were included for 
data analysis. The peak amplitudes of tail currents before and after compound treatment were 
measured. Compound effects were assessed by the percentage change in the hERG tail current. 
The percentage changes were calculated by dividing the difference between pre- and post-
compound hERG tail currents by the respective pre-compound tail current in the same well and 
normalized to positive and negative controls in the same plate.  
Whole-cell currents were measured in the following recording buffers: 137 mM NaCl, 4 mM KCl, 
1 mM MgCl2, 1.8 mM CaCl2, 10 mM HEPES, and 10 mM glucose, pH 7.4 adjusted with NaOH 
(extracellular solution); 40 mM KCl, 100 mM K-gluconate, 1 mM MgCl2, and 5 mM HEPES, pH 
7.2 adjusted with KOH (intracellular solution).  
 
 Data Analysis 
 Manual Patch clamp and FluxOR data was analyzed similarly as in Chapter II. Peaky steady 
state currents were used for dose response measurements. The automated patch-clamp 
experiments were analyzed in IonWorks® 2.0.4.4. Further calculations were performed in Excel. 






 A small selection of CNS active compounds was acquired for assays (Table 3.1). Compounds 
screened twice using the Ionworks PPC assay (Figure 3.1) and in the FluxOR assay once. In 
order to evaluate accuracy, results were compared to literature values report for Kv11.1-1A. Due 
to high variance of results in the literature, the vast majority of reference values were taken from 
the NCI PubChem compound database or regulatory reports with preference given to values 
obtained via manual patch clamp in CHO-K1 or HEK 293 cells.221  
 Initial runs from Ionworks were largely inconsistent with reported values for inhibition of 
Kv11.1-1A. However, it is know that this platform is unable to accurately assess potent 
compounds, especially highly lipophilic species. Therefore, an additional screen was run on 8 
selected compounds with an increased compound incubation time of 8 minutes total. Nearly all 
compounds showed higher potency with the increased incubation time with the exception of 
ziprasidone.  
 Many compounds were found to be selective for Kv11.1-3.1, up to 4-fold (olanzapine). No 
compound was found to be significantly selective for Kv11.1-1A.  
 Results in the FluxOR assay were closer to literature values than Ionworks for some compounds 
(chlorpromazine, pimozide, thioridazine, etc.), but not for others (amitriptyline, illoperidone, 
quetiapine, etc.). When possible to determine, selectivity for 3.1 was mostly conserved between 
assays.  
 Due to its consistent selectivity in the Ionworks and FluxOR assays (2 and 5-fold, respectively), 
promising clinical exposure levels, and idiosyncratic polypharmacological profile and clinical 
efficacy, clozapine was selected for manual patch validation Clozapine was found to be 





















Figure 3.2. Clozapine is significantly selective for Kv11.1-3.1. BacMam transduced HEK 293 
cells were patched in whole-cell voltage clamp mode and clozapine was titrated for dose-response 
measurements from peak steady-state currents (n=3 for each group). Clozapine had an IC50 of 2.4 




 In this study, many molecules were found to be selective in either one or both of the screening 
assays. Amisulpride, lurasidone, quetiapine, sertindole, and thioridazine, were found to be 
selective in Ionworks but were not validated in FluxOR. The FluxOR assay, in general, did not 
yield many unilaterally selective results (asenapine, cisapride control). No compound was found 
to be Kv11.1-1A selective, which may be due to the lower overall current density accumulation 
of Kv11.1-3.1 channels. Of concern is an artificial effect, although the pulse protocols used for 
both cells should not have resulted in any inherent preference for either channel.187 There may be 
fewer channels on the surface for the Kv11.1-3.1 cells, although the work in Chapter II 
concerning surface and total expression argues against this theory. 
 Amitriptyline, a common tricyclic anti-depressant with known Kv11.1-1A activity, was selective 
in both assays. Although amitriptyline is known to exacerbate psychotic symptoms in patients 
with schizophrenia, and thus was not of interest for the purpose of examining a potential role of 
Kv11.1-3.1 in schizophrenia pathology, it may prove to be a useful tool in the future due to this 
interesting activity profile. Risperidone was validated as being selective in the Ionworks assay, 
although this effect was less than 2-fold in the FluxOR assay. As risperidone has been previously 
characterized as selective in manual patch clamp, this may suggest that the FluxOR assay may 
underreport compound selectivity between isoforms, perhaps leading to the fewer selective 
species as noted.189 Olanzapine was found to be nearly 4-fold selective in the IonWorks assay, in 
contrast to a previously reported manual patch clamp report.189 Unfortunately, olanzapine was not 
active in the FluxOR assay, warranting continued investigation especially considering the clinical 
implications in patients harboring KCNH2-3.1 inducing risk SNPs.186  
 Clozapine was the only compound followed up with manual patch validated as mentioned. The 
magnitude of the observed selectivity by manual patch (2-fold) was not as large as the screening 
assays (2.5-fold IonWorks, 5-fold FluxOR), although selectivity was consistent across all three 
assays in contrast to a previous report of non-selectivity by Heide et al.189 This may be due to 
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differences in methods used, as Heide et all used a highly controlled perfusion system to quickly 
flow compounds for 20s. In this study, compound doses were applied until the current was 
stabilized after multiple pulse cycles, lasting up to 5 minutes in some cases. Both methods have 
advantages and the physiological relevance of using either is a matter of debate. While these 
results need verification and follow-up in more relevant systems such as neuronal cultures from 
KCNH2-3.1 overexpressing mice, a putative conservation of selectivity may implicate Kv11.1-
3.1 action in clozapine antipsychotic efficacy. Indeed, total brain concentration of clozapine in 
average schizophrenia patients has been estimated in the low micromolar range, which may exist 
in the proposed selectivity window for Kv11.1-3.1.221,222 Further studies comparing clinical 
outcomes from patients prescribed clozapine segmented by KCNH2-3.1 increasing risk SNPs are 
needed. 
 However, the implications of these screening results are restricted as this study has severe 
limitations. Reported Kv11.1-1A activity of the CNS-active compounds in this test was not 
routinely reflected in the experimentally found values (see references in Table 3.1). While the 
PubChem database represents a convenient database for Kv11.1-1A activity of various drugs, 
these values have been mostly taken from a handful of papers without any meta-analysis or 
comparison. Additionally, the primary sources used different methods to obtain activity, not only 
by cell type, but also voltage protocol. This lead to discrepancies, due to different modes of 
actions/binding preferences. This is also common in the literature for other sources of reported 
values Kv11.1-1A potency values. (Table 3.1). Additionally confounding the comparison of 
experimental results, each assay may display compound-specific inaccuracies due to solubility 
issues or assay limitations. For example, FluxOR does not reflect true electrophysiology and thus 
is unable to cycle through channel states, limiting the activity of some drugs that may 
preferentially bind to the inactivated state or those especially prone to drug-trapping. Additionally, 
it has been shown that FluxOR assays can underreport potency and is prone to high-variance for 
many compounds.125,128 The APC platform (IonWorks Quattro™) is prone to variance from 
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compound specific interactions, poor seals, and batch-to-batch cell variation, (this machine has 
been upgraded with more accurate technology recently.)223 Additionally, this assay is known to 
exhibit reduced-potency shifts similar to this report.224 Nevertheless, the combination of these two 
assays in parallel with manual patch validation for specific hits has been reported as a useful 
strategy from Kv11.1-1A.225 
 We report that this same strategy is viable for Kv11.1-3.1 screening, and has been used to show 
that clozapine is a selective inhibitor, with potencies in the range of therapeutic brain 
concentrations. If validated, the contribution of Kv11.1-3.1 to schizophrenia pathology may 
partially explain the unique efficacy of clozapine in schizophrenia. Further studies and drug 
discovery efforts may be able to emulate these activities of clozapine in new chemical classes that 
are without the devastating adverse effects associated with clozapine, most notably, 
agranulacytosis.24 However, it is still not known how much inhibition of Kv11.1-3.1, if any, 
provides a putative therapeutic effect, if at all. The synthesis of a more selective tool compound 




Table 3.1. Antipsychotic and CNS active compound collection. Literature value references: a, 
Silvestre et al.221 b, Tie et al.226 c, Brown227  d, Callier et al.228 e, Yoshida et al.229 f, Vigneault et 
al.230 g, Spyker et al.231 h, Brown et al.232 i, Kongsamut et al.233 j, Dosa et al.234  * Values taken 




Compound Structure Reported Voltage 
Clamp IC50 (µM) 
Ion Works IC50 (µM) FluxOR IC50 (µM) 



































































































































































































































































































































































































































































































Discovery of Amino-Acetamides as selective Kv11.1-3.1 inhibitors 
 
Introduction 
 While Kv11.1-3.1 is a promising target for small-molecule therapeutics, there are a number of 
challenges with translating these findings into the clinic. Most prominent of these issues is 
structural homology to Kv11.1-1A, principal contributor to cardiac IKr currents and prolific drug 
discovery “anti-target” due to blockade resulting in arrhythmia, long QT syndrome, and torsades 
de pointes.128 Several drugs, including many antipsychotics, are known to inhibit hERG, thus it is 
critical to ensure selective modulation of Kv11.1-3.1 and counter-screen for IKr activity.172 While 
hERG binding amongst drug-like compounds is largely promiscuous, some key factors have been 
identified, such as π-cation interaction and π-π stacking with key aromatic residues Y652 and 
F656 in the channel pore.166 These areas are conserved in the Kv11.1-3.1 channel, and it is 
unknown whether this N-terminal truncation distorts relative tertiary and quaternary structures, 
leading to the possibility of creating selective inhibitors.176 However, differential drug binding 
has been shown for homologous K channels exhibiting variable pore structure and sequences, 
lacking C-type inactivation, while conserving the key aromatic-side chains.128 Residues on the 
interface of the selectivity filter have also been reported to affect pore-block binding, although 
these are highly conserved amongst Kv channels and are not thought to play a prominent role in 
high-affinity, promiscuous drug binding.128  
 Recognizing the difficulty in designing potent and selective molecules de novo, a high 
throughput screen of the NIH Molecular Library Program (MLP) small molecule library was 
performed at the National Center of Chemical Genomics utilizing a 1536 well FluxOr thallium-
77 
 
flux assay (PUBCHEM AID 720544).125,235 From these efforts a family of molecules with mid 
nanomolar to low micromolar potency and greater than 10-fold selectivity was identified. Most 
promising of these compounds was compound 1 (Figure 1) which displayed mid nanomolar 
potency and 50-fold selectivity for the 3.1 channel, verified using whole-cell patch clamp. From 
this hit led the development of this study, in which structure-activity relationships of synthesized 
analogs were investigated for activity against Kv11.1-1A (hERG) and Kv11.1-3.1 (3.1) using the 























Chemistry and SAR analysis 
 A broad spectrum approach was taken to modify the lead via modification of 3 regions: 1) 
western azepane ring, 2) eastern piperidine ring, and the 3) acylated aniline core (Figure 1). 
Without crystal structures to guide analog synthesis, two general theoretical routes were 
considered in achieving the desired properties of selectivity, potency, and blood-brain penetration: 
1) reduce potency on Kv11.1-1A (hERG) using transformations from the medicinal chemistry 
literature166, 2) increase selectivity through discrete spatial modifications that inherently increase 
preferential Kv11.1-3.1 binding (empirically determined) and 3) retain chemical properties 
suitable for crossing the blood-brain barrier .   
 Optimizing compounds to reduce hERG activity has been thoroughly discussed and reported,128 
with the most general methods involving reductions of basic nitrogen pKa and lowering of LogD. 
Analogs were synthesized that made variations to the three regions of interest, choosing 
secondary amines and heterocycles that resulted in subtle changes in size, total polar surface 
area/cLogD, and pKa.166 
 Analogs containing derivatives of the azepane ring (Table 4.1) were constructed via synthesis 
(Scheme 4.1) of an intermediate 4 that could be readily substituted via Buchwald-Hartwig 
coupling236 with various secondary amines. Surprisingly, all of the synthesized azepane ring 
analogs resulted in a substantial loss of potency for both forms of the channel, with only 5 
maintaining activity for Kv11.1-3.1 below 10 µM. These very small changes in ring size, polarity, 
and basicity were not tolerated, suggesting subtle contributions from the azepane geometry or pKa 
being critical for high potency. Based on these initial results, efforts were focused on 
modification of the core region of 1 as well as the eastern piperidine. 
 Modification of the eastern piperidine was accomplished through synthesis of intermediate 12 









Scheme 4.1. Synthesis of western azepane analogs. 
 
 
Reagents and conditions:  a) chloroacetyl chloride, TEA, CH2Cl2, 0 ⁰C  b) piperidine, K2CO3, 









Table 4.1. Modifications to azepane ring 
  
























































































Scheme 4.2. Synthesis of eastern piperidine analogs. 
 
 
Reagents and conditions: a) azepane, K2CO3, MeCN, 80 ⁰C b) 10% Pd(C), 1 atm H2, EtOH c) 










with various secondary amines via nucleophilic addition to yield derivatives 13-28 in good yields. 
Initial modifications (Table 4.2) were made to attenuate the pKa of the nitrogen in the resulting 
compound. Decreasing the contained nitrogen’s basicity through inductive effects of oxygen in 
the ring or fluorine substitution reduced potency and selectivity (compounds 13-17). Compounds 
with diminished pKa but with greater reductions in cLogD via hydroxyl/H-bond donor 
substituents, 18-20 and 27 also displayed poor activity. The most potent of the reduced pKa 
compounds was 28, although non-selective (having similar terminal structure to haloperidol, a 
typical antipsychotic and potent hERG blocker189).  
 Compounds with higher or comparable basicity and slightly larger modifications were 
synthesized looking for positions where polarity would be tolerated in Kv11.1-3.1 but not 
Kv11.1-1A. While some small differences in potency and selectivity were seen with various 
hydroxyl-containing analogs (compounds 18-22), all lost more potency on Kv11.1-3.1 than 
Kv11.1-1A compared to 1. Carboxylic acid additions to the core which create zwitterionic species 
such as compounds 24 and 25 were prepared to explore this well-known mode of hERG potency 
reduction.237  However, these additions eliminated activity on both forms of the channel 
regardless of the substitution pattern on the piperidine.  Incorporation of additional polarity by 
addition of amines or acetamides, exemplified by compounds 26 and 27, significantly reduced 
cLogD but also lost measurable activity on the channel.  
 Without any improvements from general modifications to physiochemical properties, more 
significant spatial changes were explored (Table 4.3). Incremental piperidine ring reduction to 
compound 29 was not tolerated; however, expansion to compound 30 resulted in only a 2-fold 
loss of potency with conserved selectivity. In response, a compromise between the piperidine and 




Table 4.2. Polarity and pKa-varying modifications to piperidine ring 
 








































































































































































































































































































The 2-substituted methylpiperidine 31 was well tolerated, having near identical activities to 1. 
While 32 and 33 had similar Kv11.1-1A activity to 1 and 31, their 3.1 potency was between 4-5 
fold lower, diminishing their selectivity in kind as anticipated by previous modifications (vide 
supra).  
 Seeking to probe additional space through larger additions, pendant phenyl groups were added in 
similar fashion as methyl substitutions to the piperidine. Paradoxically, 2-substituted piperidine 
34 displayed higher selectivity than the 3-substituted variants 35 and 36, but lower potency. Both 
35 and 36 were highly potent on Kv11.1-3.1 with low selectivity. Combining the most selective 
modifications from the phenyl and methyl additions, compound 37 was unable to improve 
potency or conserve selectivity as a mixture of isomers. In attempts to compensate for pendant 
phenyl addition with piperidine ring reduction, 2-substiututed pyrrolidine 38 was not tolerated. 
The 3-substituted variant 39 had only modest losses in 3.1 activity, but large gains in Kv11.1-1A 
to the detriment of selectivity.  
 Increasing space, but limiting extension to that of the 2’-positions, the bicyclo compound 40 was 
the most potent in the series with a 3-fold increase in potency and conservation of selectivity. 
However, the Kv11.1-1A potency was considered suboptimal, being lower than 10 µM.    
 Initial modifications (Table 4.4) to the linker were synthesized via acylating 11 with 
chloroacetyl chloride analogs (Scheme 4.2) prior to nucleophilic substitution with piperidine. The 
linker was extended or methylated on the α carbon to restrict rotation, yielding compounds 41 and 
42 respectively. Neither compound was tolerated, discouraging further linker analogs. 
 Concerns over the dianiline species being a metabolic hotspot for cytochrome P450-mediated 
metabolism, which may result in a potentially toxic reactive species, prompted efforts to attenuate 
the electron rich aromatic core.238 To achieve this and improve ADME properties through 




Table 4.3. Spatial Modifications to Piperidine Ring 
 



















































































































































































































































Table 4.4. Linker Modifications 
  


























































































































































evaluation of heterocycles containing 1 and 2 nitrogen atoms at each position of the core showed 
substantial losses in potency with the exception of pyridine derivative 46.  Interestingly, this was 
the only modification that increased azepane nitrogen pKa. Although exhibiting a 10-fold loss in 
potency on Kv11.1-3.1, 46 retained selectivity, greater than can be determined by the assay. The 
other pyridine analog 47 was not tolerated with a 100-fold loss in activity as well as pyridazine 50. 
While pyrimidine 51 retained some selectivity, it lost significant Kv11.1-3.1 potency. Pyrazine 52 
exhibited the lowest resulting azepane pKa and no channel activity. Fluorine substitution 
produced core analogs 53 and 54 which were surprisingly different in their potency and 
selectivity. The calculated change in the azepane nitrogen pKa was nearly a log unit different, 
suggesting that the basicity of this nitrogen may be an important factor that selectively drives 
Kv11.1-3.1 potency.   
 Seeking to balance the potency of bicyclic derivative 34 with the selectivity and improved 
physical properties of 46, compound 55 was synthesized as shown in Scheme 4.2. Compound 55 
was slightly more potent than 1 but with greatly augmented selectivity and a more desirable 
cLogD and TPSA for brain penetration. This activity was verified by manual patch which 
reported increased potencies on Kv11.1-3.1 and Kv11.1-1A, although to a slight detriment to 
selectivity (Table 4.7). Compound 55 calculated chemical properties yielded a MPO score239 of 
5.2, according to Wager et al., suggesting a greater probability of blood-brain barrier penetration.  
  Compounds 1, and 46 were assayed for stability and intrinsic clearance using rat liver 
microsomes supplemented with NADPH, UDPGA, and alamethicin.  Promising stability was 
observed, prompting a more complete evaluation of 55 in vivo (Table 4.7). Compound 55 was 
evaluated for mouse blood-brain barrier penetration and pharmacokinetics in rats. It was found 
that 55 was able to penetrate the mouse blood-brain barrier at a ratio of 16:1 total brain:plasma, at 
IC50 relevant concentrations for up to two hours. However, at eight hours there was no more 
compound detected, hinting at rapid clearance. This was indeed confirmed in the rat 
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pharmacokinetic studies which showed no detectable 55 after only 5 minutes of being dosed 
10mg/kg orally. These results indicate that metabolite identification studies must be carried out to 
resolve the pharmacokinetic issues. A compound with a longer half-life must be synthesized, as 
the current compounds are not amenable to behavioral studies which require longer compound 
exposure.   
Beyond translational aims, this work offers clues that may potentially guide new insight into 
unknown aspects of Kv11.1-3.1 structure and pharmacology. Despite complete transmembrane 
and pore sequence conservation,176 this report, stemming from data from an initial high 
throughput screen, suggests that selective inhibition is indeed possible and is able to be 
manipulated via novel compounds. It has been previously reported that risperidone inhibits 
Kv11.1-3.1 with 2-fold greater potency than Kv11.1-1A, although the structural mechanism of 
selectivity is perplexing as most hERG blockers are thought to bind in the channel pore.128,189 It 
may be possible that the lack of interactions, facilitated with the N-terminal PAS domain, has 
resulted in modified tertiary and quaternary channel structure. This may lead to new binding 
pockets within the pore. However, the possibility of binding regions outside the channel is still 
possible. While there is no crystal structure of Kv11.1-1A or Kv11.1-3.1128, it may be of use to 

































Structure Compound Ti Flux (nM) 
1A          3.1      
Patch  (nM) 
 1A          3.1      

























































Table 4.7. Electrophysiology summary and in vitro rat liver microsome stability data 
 
Time (hr) 
Compound 55 Concentration 
Brain-to-Plasma 
Ratio 
Brain (ng/g) Plasma (ng/mL) 
0.5 2200 ± 1100 100 ± 52 22 
1 920 ± 74 57 ± 8 16 
2 290 ± 160 18 ± 3 16 
8 BLQ BLQ N/A 
 
Table 4.8. Compound 55 c57 mouse blood-brain barrier summary.  
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Materials and Methods 
 
 Synthesis 
 All commercially available reagents and solvents were used without further purification. 
Automated flash chromatography was performed on Biotage Flash Isolera using Biotage Flash 
cartridges with peak detection at 254 nm. Reverse phase purification was accomplished using a 
Gilson GX-271 liquid handler equipped with a Phenomenex Luna C18 column (50 mm X 21.2 
mm i.d., 5 µm). Peak collection was triggered by UV detection at 254 nm. 1H NMR spectra were 
recorded on a Bruker 400 instrument operating at 400 MHz with residual DMSO used as a 
reference. Analytical LC/MS was performed using Agilent 1260 equipped with autosampler 
(Agilent Poroshell 120 C18 column; 50mm X 4.6 mm i.d.; 3.5 µM); 0.05% TFA in 
water/acetonitrile gradient; UV detection at 254 nm) and electrospray ionization. All final 
compounds showed purity greater than 95% and 254 nm using this method. 
 
N-(4-bromophenyl)-2-chloro-acetamide (3) 
 To a stirring 0 oC solution of 5g (29.07 mmol) (2) and 12.09 mL (87.2 mmol) triethylamine in 
100 mL CH2Cl2, 2.86 mL (29.07 mmol) chloroacetyl chloride was added drop wise into the 
solution and allowed to warm to room temperature for 24 hours. The reaction mixture was then 
diluted with CH2Cl2, washed with 1N aqueous hydrochloric acid, washed with brine, and then 
dried over sodium sulfate. The mixture was filtered, concentrated and purified by flash 
chromatography (Biotage Isolera One, 100g silica gel, linear gradient 0-50% EtOAc:heptanes) to 
yield 2.92 g of (3) (40%). 1H NMR (Chloroform-d, 400 MHz) : 8.24 (br s, 1H); 7.47 (d, 4H, 





To a stirring solution of 2.85 (11.47 mmol) (3) and 3.96 g (28.67 mmol) potassium carbonate in 
50 mL CH3CN, 1.53 g (12.6 mmol) piperidine hydrochloride was added. The reaction mixture 
was stirred at 80 oC for 6 hours. The solution was cooled to room temperature, filtered and 
concentrated. The residue was crystallized from ether/heptane to give 3.03 g of (4) (89%). 1H 
NMR (Chloroform-d, 400 MHz) : 9.31 (br s, 1H); 7.47 (d, 4H, J=11.7 Hz); 3.06 (s, 2H); 2.56 
(br s, 4H); 1.67-1.63 (m, 4H); 1.50 (m, 2H). MS [M+1]=297 
 
2-(1-piperidyl)-N-[4-(1-piperidyl)phenyl]acetamide HCl (5) 
To a stirring solution of 0.1g (0.34 mmol) (4), 0.043 g (0.5 mmol) piperidine and 0.329 g (1.01 
mmol) cesium carbonate in 2 mL DMSO, 0.012 g (0.02 mmol) Xanphos precat G2 240 was added. 
The reaction mixture was heated to 110 oC for 12 hours. The solution was filtered, purified by 
reverse phase HPLC (C18, linear gradient 10%-95% CH3CN/Water, 0.05% TFA additive), 
concentrated, then treated with 2N HCl in ether and filtered to afford 0.043 g of (5) (38%). 1H 
NMR (DMSO-d6, 400 MHz) : 10.04 (br s, 1H); 7.92 (d, 2H, J=8.1 Hz)); 7.81 (d, 2H, J=9.1 Hz) 
4.20 (d, 2H, J=4.8 Hz); 3.48 (d, 6H, J=8.3 Hz); 3.11 (m, 2H); 2.16-1.40 (m, 12H). MS 
[M+1]=302.2 
 
2-(1-piperidyl)-N-(4-pyrrolidin-1-ylphenyl)acetamide hydrochloride (6) 
To a stirring solution of 0.1 g (0.34 mmol) (4), 0.035 g (0.5 mmol) pyrrolidine, and 0.329 g (1.01 
mmol) cesium carbonate in 2 mL DMSO, 0.012 g (0.02 mmol) Xanphos precat G2 was added. 
The reaction mixture was heated to 110 oC for 12 hours. The solution was filtered, purified by 
reverse phase HPLC (C18, linear gradient 10%-95% CH3CN/Water, 0.05% TFA additive), 
concentrated, then treated with 2N HCl in ether and filtered to afford 0.022 g of (6) (20%). 1H 
NMR (DMSO-d6, 400 MHz) : 9.92 (br s, 1H); 7.56 (d, 2H, J=7.8 Hz); 7.01 (m, 2H); 4.11(m, 
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2H); 3.47-3.01 (m, 8H); 2.01 (m, 2H); 1.77 (m, 6H). MS [M+1]=288.2  
 
N-(4-morpholinophenyl)-2-(1-piperidyl)acetamide hydrochloride (7) 
To a stirring solution of 0.1 g (0.34 mmol) (4), 0.044 g (0.5 mmol) morpholine, and 0.329 g (1.01 
mmol) cesium carbonate in 2mL DMSO, 0.012 g (0.02 mmol) Xanphos precat G2 was added. 
The reaction mixture was heated to 110 oC for 12 hours. The solution was filtered, purified over 
Gilson reverse phase HPLC (C18, linear gradient 10%-95% CH3CN/Water, 0.05% TFA additive), 
concentrated, then treated with 2N HCl in ether and filtered to afford 0.012 g of (7) (10%). 1H 
NMR (DMSO-d6, 400 MHz) :9.85 (br s, 1H); 7.55 (d, 2H, J=8.6 Hz); 7.13 (br s, 2H); 5.19 (br s, 
4H); 4.10 (d, 2H, J=5.1 Hz); 3.80 (br s, 4H); 3.47 (d, 2H, J=11.6 Hz); 3.09-3.02 (m, 2H); 1.78-
1.66 (m, 6H). MS [M+1]=303.3  
 
N-[4-(1,4-oxazepan-4-yl)phenyl]-2-(1-piperidyl)acetamide hydrochloride (8) 
To a stirring solution of 0.1 g (0.34 mmol) (4), 0.054 g (0.5 mmol) 1,4-oxazepane, and 0.329 g 
(1.01 mmol) cesium carbonate in 2mL DMSO, 0.012 g (0.02 mmol) Xanphos precat G2 was 
added. The reaction mixture was heated to 110 oC for 12 hours. The mixture was filtered, purified 
over Gilson reverse phase HPLC (C18, linear gradient 10%-95% ACN/Water, 0.05% TFA 
additive), and then treated with 2N HCl in ether to afford 0.026 g of (8) (21%). 1H NMR (DMSO-
d6, 400 MHz) : 10.81(s, 1H); 7.63 (m, 2H); 7.40 (m, 2H); 4.41 (br s, 4H); 4.13 (d, 2H, J=5 Hz); 
3.55-3.45 (m, 4H); 3.11-3.01 (m, 4H); 1.79-1.68 (m, 6H); 1.39 (m, 2H). MS [M+1]=332.2 
 
1-(4-nitrophenyl)azepane (10) 
To a stirring solution of 5 g (35.44 mmol) (9) and 4.39 mL (38.98 mmol) azepane in 50 mL 
CH3CN, 12.24 g (88.59 mmol) potassium carbonate was added. The reaction mixture was stirred 
at 70 oC for three hours. The solution was diluted with ethyl acetate, washed with water, dried 
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with MgSO4, filtered, concentrated and purified by flash chromatography (Biotage Isolera One, 
100g silica gel, linear gradient 0-10% MeOH:CH2CL2) to afford 7.6 g of (10) (97%). 1H NMR 
(Chloroform-d, 400 MHz) : 8.11(d, 2H, J=9.4 Hz); 6.63 (d, 2H, J=9.3 Hz); 3.57 (t, 4H, J=6.1 
Hz); 1.85 (m, 4H); 1.59 (m, 4H). MS [M+1]=221.1 
4-(azepan-1-yl)aniline (11) 
To a solution of 7.6 g (34.5 mmol) (10) in 100 mL ethanol, 2g (34.5 mmol)10% palladium on 
carbon was added. The solution was stirred under 1 atm hydrogen gas for 24 hours. The solution 
was filtered and concentrated to give 6.4 g of (10) (97%). 1H NMR (Chloroform-d, 400 MHz) : 
6.67-6.56 (m, 4H); 3.4 (m, 4H); 3.22 (m, 2H); 1.78 (br s, 4H); 1.46-1.68 (m, 4H). MS 
[M+1]=190.1 
N-[4-(azepan-1-yl)phenyl]-2-chloro-acetamide (12) 
To a solution of 0.5 g (2.62 mmol) (11) in 13mL CH2Cl2 was added 330 µL (2.4 mmol) 
triethyamine.  The reaction mixture was stirred for 1 minute then to which was added 251 µL (3.2 
mmol) chloroacetyl chloride. The reaction mixture was stirred and allowed to warm to room 
temperature for two hours and then diluted with 20 mL CH2Cl2, washed with water, dried over 
MgSO4, filtered, and concentrated.  Purification by flash chromatography ( Biotage Isolera One, 
24g silica gel, linear gradient 20%-60% EtOAc:heptanes) afforded 0.651 g of (11) (93%). 1H 
NMR (DMSO-d6, 400 MHz) 9.97 (s, 1H); 7.37 (d, 2H, J=8.6 Hz); 6.66 (br s, 2H); 4.18 (s, 2H); 
3.44 (t, 4H, J=5.8 Hz); 1.72 (m, 4H); 1.46 (m, 4H). MS [M+1]=267.1 
 
General procedure A 
 To a stirring solution of 0.030 g (0.112 mmol) (12) in 1 mL DMF was added 3 equivalents 
piperdine or other appropriate secondary amine from Tables B or C, which was then heated to 
80°C for 3-18 hours. The reaction mixture was then diluted with 0.5 mL MeOH and purified by 
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reverse phase HPLC (C18, linear gradient 10%-95% ACN/Water, 0.05% TFA additive). 
Resulting purified compounds were tested as 1:1 TFA salts unless otherwise noted. 
 
N-[4-(azepan-1-yl)phenyl]-2-morpholino-acetamide hydrochloride (13) 
Prepared according to General Procedure A yielding 0.04 g (30%). 1H NMR (DMSO-d6, 400 
MHz) : 10.42 (s, 1H); 7.41 (br s, 2H); 6.70 (br s, 2H); 4.14 (br s, 2H); 3.94 (br s, 2H); 3.95 - 
3.78 (m, 2H); 3.44 (br s, 6H); 3.27 (br s, 2H); 1.73 (br s, 4H); 1.47 (br s, 4H). MS [M+1]=318.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(1,4-oxazepan-4-yl)acetamide hydrochloride (14) 
Prepared according to General Procedure A yielding 0.02 g (15%). 1H NMR (DMSO-d6, 400 
MHz) : 10.34 (br s, 1H); 7.52 (br s, 2H); 6.79 (br s, 2H); 4.22 (s, 2H); 3.90- 3.69 (m, 4H); 3.53-
3.39 (m, 8H); 2.25-1.55 (m, 10H). MS [M+1]=332.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(3-fluoro-1-piperidyl)acetamide (15)  
Prepared according to General Procedure A yielding 0.043 g (94%). 1H NMR (DMSO-d6, 400 
MHz)  10.23 (s, 1H); 7.36 (d, 2H, J=9.1 Hz); 6.67 (d, 2H, J=8.8 Hz); 5.15 (m, 1H); 4.13 (m, 2H); 
3.8 (m, 1H); 3.43 (m, 5H); 3.22 (br s, 1H); 2.49 (m, 1H); 2.07-1.91 (m, 2H); 1.77-1.70 (m, 6H); 
1.47-1.44 (m, 4H). MS [M+1]=334.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(4,4-difluoro-1-piperidyl)acetamide (16) 
Prepared according to General Procedure A yielding 0.014 g (10%).1H NMR (DMSO-d6, 400 
MHz) : 10.62 (br s, 1H); 7.49 (br s, 2H); 6.86 (br s, 2H); 5.61 (br s, 4H); 4.24 (s, 2H); 3.65-3.39 
(m, 8H); 2.00-1.53 (m, 8H). MS [M+1]=351.2 
 
N-[4-(azepan-1-yl)phenyl]-2-[2-(trifluoromethyl)-1-piperidyl]acetamide (17)   
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Prepared according to General Procedure A yielding 0.010 (18%).  1H NMR (DMSO-d6, 400 
MHz)  9.45 (s, 1H); 7.41 (d, 2H, J=7.8 Hz); 6.76 (br s, 2H); 3.70 (m, 1H); 3.46-3.39 (m, 5H); 
2.89-2.73 (m, 2H); 1.74-1.46 (m, 14H). MS [M+1]=384.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(4-hydroxy-1-piperidyl)acetamide (18)  
Prepared according to General Procedure A yielding 0.038 g (76%). 1H NMR (DMSO-d6, 400 
MHz)  10.24 (s, 1H); 7.37 (m, 2H); 6.67 (d, 2H, J=8.8 Hz); 5.45 (br s, 1H); 4.07 (m, 2H); 3.93 
(br s, 1H); 3.49 (m, 1H); 3.44 (t, 4H, J=6 Hz); 3.31 (m, 2H); 3.12 (m, 1H); 1.95 (m, 2H); 1.70 (br 
s, 6H); 1.45 (m, 4H). MS [M+1]=332.0 
 
N-{4-(azepan-1-yl)phenyl}-2-(4,4-dihydroxyt-1-piperidl)acetamide (19)                                                                                                           
Prepared according to General Procedure A yielding 0.018 g (34%). 1H NMR (DMSO-d6, 400 
MHz)  9.46 (s, 1H); 7.39 (d, 2H, J=8.9 Hz); 6.62 (d, 2H, J=9.1 Hz); 3.43 (t, 4H, J=6.1 Hz); 3.22 
(s, 2H); 2.85 (t, 4H, J=6 Hz); 2.43 (t, 4H, J=6 Hz); 1.70 (m, 5H); 1.45 (m, 5H). MS [M+1]=348.3 
 
N-[4-(azepan-1-yl)phenyl]-2-[4-(hydroxymethyl)-1-piperidyl]acetamide  (20)  
Prepared according to General Procedure A yielding 0.031 g (60%). 1H NMR (DMSO-d6, 400 
MHz)  10.25 (s, 1H); 7.36 (d, 2H, J=9.1 Hz); 6.67 (d, 2H, J=9 Hz); 4.02 (m, 2H); 3.53 (m, 2H); 
3.43 (t, 4H, J=5.9 Hz); 3.27 (m, 3H); 3.05 (m, 2H); 1.84 (m, 2H); 1.70 (br s, 4H); 1.61 (m, 2H); 
1.51-1.43 (m, 5H). MS [M+1]=346.3 
 
N-[4-(azepan-1-yl)phenyl]-2-[2-(hydroxymethyl)-1-piperidyl]acetamide (21)  
Prepared according to General Procedure A yielding 0.008 g (15%). 1H NMR (DMSO-d6, 400 
MHz)  1H NMR (CD3SO, 400 MHz)  10.29 (s, 1H); 7.43 (m, 5H); 7.27 (d, 1H, J=7.3); 6.67 (d, 
1H, J=8.8 Hz) 4.07 (s, 2H); 3.55 (m, 2H); 3.44 (t, 5H, J=5.8 Hz); 3.32-3.17 (m, 2H); 1.94 (m, 4H); 
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1.70 (m, 5H); 1.45 (m, 4H). MS [M+1]=346.3 
 
N-[4-(azepan-1-yl)phenyl]-2-[4-(1-hydroxy-1-methyl-ethyl)-1-piperidyl]acetamide (22)  
Prepared according to General Procedure A yielding 0.019 g (35%). 1H NMR (DMSO-d6, 400 
MHz)   
10.23 (s, 1H); 7.35 (d, 2H, J=9.1 Hz); 6.67 (d, 2H, J=8.8 Hz); 4.00 (d, 2H, J=5.1 Hz); 3.54 (m, 
3H); 3.43 (t, 4H, J=5.8 Hz); 3.30 (m, 2H); 1.85 (m, 4H); 1.70-1.60 (m, 7H); 1.44-1.36 (m, 8H). 
MS [M+1]=374.3 
 
N-[4-(azepan-1-yl)phenyl]-2-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)acetamide (23)  
Prepared according to General Procedure A yielding 0.038 g (69%). 1H NMR (DMSO-d6, 400 
MHz)  10.26 (s, 1H); 7.37 (d, 2H, J=9.1 Hz); 6.68 (d, 2H, J=9.1 Hz); 4.13 (s, 2H); 3.94 (s, 4H); 
3.56 (m, 2H); 3.44 (m, 4H); 3.22 (m, 2H); 2.09 (m, 2H); 1.86 (m, 2H); 1.71 (br s, 4H); 1.46 (m, 
4H). MS [M+1]=374 
 
1-[2-[4-(azepan-1-yl)anilino]-2-oxo-ethyl]piperidine-4-carboxylic acid (24)  
Prepared according to General Procedure A yielding 0.016 g (35%). 1H NMR (DMSO-d6, 400 
MHz)  10.24 (s, 1H); 9.77 (br s, 1H); 7.36 (d, 2H, J=9.1 Hz); 6.67 (br d, 2H, J=9.1); 4.04 (br s, 
2H); 3.55 (br d, 2H, J=2.7 Hz); 3.44 (m, 5H); 3.16 (m, 2H); 2.07 (m, 2H); 1.89 (m, 2H); 1.7 (m, 
4H); 1.45 (m, 4H). MS [M+1]=360 
 
1-[2-[4-(azepan-1-yl)anilino]-2-oxo-ethyl]piperidine-3-carboxylic acid  (25)  
Prepared according to  General Procedure A yielding 0.019 g (43%). 1H NMR (DMSO-d6, 400 
MHz)  10.27 (s, 1H); 9.89 (br s, 1H); 7.37 (d, 2H, J=8.8 Hz); 6.67 (d, 2H, J=9.1 Hz); 4.15 (m, 
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2H); 3.65 (m, 1H); 3.49 (m, 1H); 3.44 (m, 4H); 2.96 (m, 2H); 2.07 (m, 1H); 1.86 (m, 2H); 1.70 
(m, 5H); 1.44 (m, 5H). MS [M+1]=360 
 
N-[4-(azepan-1-yl)phenyl]-2-[4-(dimethylamino)-1-piperidyl]acetamide (26) 
Prepared according to General Procedure A yielding 0.032 g (48% based on 1:2 TFA salt) 1H 
NMR (DMSO-d6, 400 MHz)  10.44 (s, 1H); 7.37 (d, 2H, J=8.8 Hz); 6.68 (d, 2H, J=9.1 Hz); 
4.09 (br s, 2H); 3.66 (m, 2H); 3.44 (m, 6H); 3.11 (m, 1H); 2.78 (s, 6H); 2.38 (m, 2H); 2.08 (m, 
2H); 1.71 (br s, 4H); 1.45 (m, 4H). MS [M+1]=359.2 
2-(4-acetamido-1-piperidyl)-N-[4-(azepan-1-yl)phenyl]acetamide (27)  
Prepared according to General Procedure A yielding 0.004 g (7%). 1H NMR (DMSO-d6, 400 
MHz)  10.23 (s, 1H); 8.02 (d, 1H, J=7.5 Hz); 7.37 (d, 2H, J=9.4 Hz); 6.68 (d, 2H, J=8.4 Hz); 
4.04 (m, 2H); 3.5 (m, 2H); 3.45 (t, 4H, J=5.5 Hz) 3.17 (m, 2H); 1.97 (m, 3 H); 1.81 (s, 3H); 1.71 
(m, 4H); 1.46 (m, 4H). MS [M+1]=373.2 
 
N-[4-(azepan-1-yl)phenyl]-2-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]acetamide (28)  
Prepared according to General Procedure A yielding 0.030 g (71%). 1H NMR (DMSO-d6, 400 
MHz)  10.26 (s, 1H); 7.50 (m, 4H); 7.38 (d, 2H, J=9.1 Hz); 6.68 (d, 2H, J=9.1 Hz); 5.63 (br s, 
1H); 4.16 (br d, 2H, J=4.6 Hz); 3.46 (m, 8H); 2.33 (m, 2H); 1.82 (br d, 2H, J=13.9 Hz); 1.71 (br s, 
4H); 1.45 (m, 4H). MS [M+1]=442.2 
 
N-[4-(azepan-1-yl)phenyl]-2-pyrrolidin-1-yl-acetamide hydrochloride (29) 
Prepared according to General Procedure A yielding 0.068 g (53%). 1H NMR (DMSO-d6, 400 
MHz) : 10.24 (br s, 1H); 7.47 (br s, 2H); 6.76 (br s, 2H); 4.20 (d, 2H, J=4.0 Hz); 3.60 (d, 2H, 




2-(azepan-1-yl)-N-[4-(azepan-1-yl)phenyl]acetamide hydrochloride (30) 
Prepared according to General Procedure A yielding 0.04 g (42%). 1H NMR (DMSO-d6, 400 
MHz) : 9.94 (br s, 1H); 7.47 (br s, 2H); 6.80 (br s, 2H); 4.13 (d, 2H, J=5.1 Hz); 3.45-3.20 (m, 
8H); 1.85-1.50 (m, 16H). MS [M+1]=330.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(2-methyl-1-piperidyl)acetamide (31)  
Prepared according to General Procedure A yielding 0.033 g (79%). 1H NMR (DMSO-d6, 400 
MHz)  10.29 (s, 1H); 7.37 (d, 2H, J=8.8, 2H Hz); 6.8 (d, 2H, J=8.8 Hz); 4.31 (dd, 1H, J=2,15.7 
Hz); 4 (m, 1H); 3.86 (dd, 1H, J=6.3, 15.4 Hz); 3.54 (br d, 1H, J=11.6 Hz); 3.44 (t, 4 H, J=5.9 Hz); 
3.37 (br d, 1H, J=6.1 Hz); 3.23 (br d, 1H, J=4.3 Hz); 1.85-1.63 (m, 9H); 1.47-1.44 (m, 5H); 1.31 
(d, 2H, J=6.3 Hz); 1.24 (d, 2H, J=6.8 Hz). MS [M+1]=330.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(3-methyl-1-piperidyl)acetamide (32)  
Prepared according to General Procedure A yielding 0.031 g (62%). 1H NMR (DMSO-d6, 400 
MHz)  10.24 (s, 1H); 7.37 (d, 2H, J=9.1); 6.68 (d, 2H, J=9.1); 4.02 (m, 2H); 3.43 (m, 6H); 2.94 
(m, 1H); 2.70 (m, 1H); 1.96 (m, 1H); 1.80-1.71 (m, 7H); 1.46 (m, 4H); 0.90 (m, 4H). MS 
[M+1]=330.3 
 
N-[4-(azepan-1-yl)phenyl]-2-(4-methyl-1-piperidyl)acetamide (33)  
Prepared according to General Procedure A yielding 0.027 g (54%). 1H NMR (DMSO-d6, 400 
MHz)  10.20 (s, 1H); 7.36 (d, 2H, J=9.1 Hz); 6.66 (d, 2H, J=9.1 Hz); 4.01 (m, 2H); 3.49-3.40 (m, 
5H); 3.25 (m, 1H); 3.04 (2H); 1.79 (m, 6H); 1.44 (m, 6H); 0.93 (m, 4H). MS [M+1]=330.3 
 
N-[4-(azepan-1-yl)phenyl]-2-[2-(4-chlorophenyl)-1-piperidyl]acetamide  (34)  
Prepared according to General Procedure A yielding 0.024 g (59%). 1H NMR (DMSO-d6, 400 
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MHz)  10.00 (s, 1H); 7.61-7.54 (m, 4H); 7.23 (d, 2H, J=9.1 Hz); 6.63 (d, 2H, J=9.1 Hz); 4.54 
(br d, 1H, J=11.1 Hz); 3.74-3.63 (m, 3H); 3.42 (t, 4H, J=5.9 Hz); 3.28 (m, 1H); 2.18 (m, 1H); 
2.04 (m, 1H) 1.90 (m, 3H); 1.69-1.6 (m, 5H); 1.44 (m, 4H). MS [M+1]=426.2 
 
N-[4-(azepan-1-yl)phenyl]-2-[3-(3-chlorophenyl)-1-piperidyl]acetamide (35)  
Prepared according to General Procedure A yielding 0.012 g (19%). 1H NMR (DMSO-d6, 400 
MHz)  1H NMR (DMSO-d6, 400 MHz)  10.29 (s, 1H); 7.43 (m, 5H); 7.27 (d, 1H, J=7.3); 6.67 
(d, 1H, J=8.8 Hz) 4.07 (s, 2H); 3.55 (m, 2H); 3.44 (t, 5H, J=5.8 Hz); 3.32-3.17 (m, 2H); 1.94 (m, 
4H); 1.70 (m, 5H); 1.45 (m, 4H). MS [M+1]=426.2 
 
N-[4-(azepan-1-yl)phenyl]-2-[4-(3-cyanophenyl)-1-piperidyl]acetamide (36) 
Prepared according to General Procedure A yielding 0.016 g (27%). 1H NMR (DMSO-d6, 400 
MHz)  10.28 (s, 1H); 7.81 (m, 2H); 7.66 (m, 2H); 7.36 (d, 2H, J=7.3 Hz); 6.67 (d, 2H, J=7.6 Hz); 
4.06 (m, 2H); 3.56 (m, 2H); 3.42-3.25 (m, 6H); 3.06 (br s, 1 H); 1.94 (m, 3H); 1.70 (br s, 5H); 
1.44 (m, 4H). MS [M+1]=417.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(2-methyl-4-phenyl-1-piperidyl)acetamide (37)  
Prepared according to General Procedure A yielding 0.045 g (77%) as a mixture of isomers. 
Data for major isomer: 1H NMR (DMSO-d6, 400 MHz)  10.30 (s, 1H); 7.39-7.24 (m, 7 H); 6.69 
(s, 2H, J=8.9 Hz); 4.37 (d, 2H, J=5.4 Hz); 3.67-3.64 (m, 2H); 3.44 (t, 4H, J=6 Hz); 3.31 (m, 1H); 
2.91 (m, 1H); 2.03-1.97 (m, 4H); 1.71 (m, 4H); 1.45 (m, 4H); 1.34 (d, 3H, J=6.4 Hz). MS 
[M+1]= 406.2 
 
N-[4-(azepan-1-yl)phenyl]-2-(2-phenylpyrrolidin-1-yl)acetamide (38)  
Prepared according to General Procedure A yielding 0.051 g (92%). 1H NMR (DMSO-d6, 400 
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MHz)  10.20 (s, 1H); 7.44-7.34 (m, 5H); 7.23 (t, 2H, J=8.9 Hz); 6.67 (d, 2H, J=8.9 Hz); 4.25 (br 
s, 2H); 3.80-3.68 (m, 2H); 3.5 (br s, 1H); 3.43 (t, 4H, J=5.9 Hz); 2.42 (m, 2H); 2.07 (m, 2H); 1.70 
(br s, 4H); 1.45 (m, 4H). MS [M+1]=378.3 
 
N-[4-(azepan-1-yl)phenyl]-2-[3-(4-fluorophenyl)pyrrolidin-1-yl]acetamide (39)  
Prepared according to General Procedure A yielding 0.055 g (96%). 1H NMR (DMSO-d6, 400 
MHz)  10.08 (s, 1H); 7.60 (m, 1H); 7.51 (m, 3H); 7.23 (d, 2H, J=8.1 Hz); 6.63 (d, 2H, J=9.1 Hz); 
4.57 (m, 1H); 4.01 (m, 2H); 3.82 (d, 1H, J=11.4); 3.42 (m, 5H); 2.40 (m, 1H); 2.18 (m, 3H); 1.69 
(br s, 4H); 1.45 (m, 4H). MS [M+1]=396.2 
 
2-(8-azabicyclo[3.2.1]octan-8-yl)-N-[4-(azepan-1-yl)phenyl]acetamide (40)   
Prepared according to General Procedure A yielding 0.027 g (52%). 1H NMR (DMSO-d6, 400 
MHz)  10.14 (s, 1H); 7.35 (d, 2H, J=8.9 Hz); 6.67 (d, 2H, J=9.1 Hz); 3.97 (br s, 2H); 3.87 (d, 
2H, J=5.5 Hz); 3.43 (t, 4H, J=6.1); 2.15 (m, 2H); 2.03 (m, 1H); 1.93 (m, 2H); 1.70 (m, 7H); 1.53 
(m, 2H); 1.45 (m, 4H). MS [M+1]=342.2 
 
N-[4-(azepan-1-yl)phenyl]-3-chloro-propanamide (41) 
 To a 4° C solution of 0.03 g (0.158 mmol) (11) in 1mL CH2Cl2 was added 20 µL (0.1435 mmol) 
triethyamine.  The reaction mixture was stirred for 1 minute then to which was added 23 µL 
(0.230 mmol) 3-chloropropionyl chloride. The reaction mixture was stirred and allowed to warm 
to room temperature for two hours and then diluted with 20 mL CH2Cl2, washed with water, dried 
over MgSO4, filtered, and concentrated which afforded 0.040 g of mixture containing (41) and 





 Prepared according to General Procedure A yielding 0.033 g (69%). 1H NMR (DMSO-d6, 400 
MHz)  9.84 (s, 1H); 7.36 (d, 2H, J=8.8 Hz); 6.66 (br d, 2H, J=8.9 Hz); 3.45 (m, 6H); 3.34 (m, 




To a 4° C solution of 0.03 g (0.158 mmol) (11) in 1mL CH2Cl2 was added 20 µL (0.1435 mmol) 
triethyamine.  The reaction mixture was stirred for 1 minute then to which was added 23 µL 
(0.230 mmol) 3-chloropropionyl chloride. The reaction mixture was stirred and allowed to warm 
to room temperature for two hours and then diluted with 20 mL CH2CL2, washed with water, 
dried over MgSO4, filtered, and concentrated in vacuo which afforded 0.040 g of mixture 
containing (43). MS [M+1]=281.2  
 
N-[4-(azepan-1-yl)phenyl]-2-(1-piperidyl)propanamide (44) 
Prepared according to General Procedure A yielding 0.031 g (66%). 1H NMR (DMSO-d6, 400 
MHz)  10.36 (s, 1H); 7.40 (d, 2H, J=9.1 Hz); 6.70 (d, 2H, J=9.1 Hz); 3.98 (t, 1H, J=6.9 Hz); 
3.55 (m, 1H); 3.45-3.35 (m, 5H); 3.07-2.89 (m, 2H); 1.80-1.71 (m, 9H); 1.53-1.45 (m, 8H) MS 
[M+1]=334.2 
 
1-(5-nitro-2-pyridyl)azepane (45a)  
Prepared from 0.2 g (1.4 mmol) 2-fluro-5-nitro-pyridine analogous to (10) yielding 0.276 g (88%). 
1H NMR (DMSO-d6, 400 MHz)  8.95 (d, 1H, J=2.8 Hz); 8.20 (dd, 1H, J=3, 9.6 Hz); 6.78 (d, 1H, 





Prepared from 0.2 g (1.4 mmol) 5-fluro-2-nitro-pyridine analogous to (10) yielding 0.220 g 
(70%).1H NMR (DMSO-d6, 400 MHz)  8.14 (d, 1H, 9.6 Hz); 8.06 (d, 1H, J=3.2 Hz); 7.26 (dd, 
1H, J=3, 9.3 Hz); 3.65 (t, 4H, J=6.1 Hz); 1.75 (m, 4H); 1.49 (m, 4H). MS [M+1]=222.2 
 
1-(6-chloropyridazin-3-yl)azepane (45c) 
Prepared from 1 g (6.7 mmol) 3,6 dichloropyridazine analogous to (10) yielding 0.510 g (35%). 
1H NMR (DMSO-d6, 400 MHz)  7.44 (d, 1H, J=9.6); 7.16 (d, 1H, J=9.6); 3.65 (m, 4H); 1.70 (m, 
4H); 1.48 (m, 4H). MS [M+1]=212.2 
 
1-(5-nitropyrimidin-2-yl)azepane (45d) 
Prepared from 0.2 g (0.98 mmol) 2-bromo-5-nitro-pyrimidine analogous to (10) yielding 0.148 g 
(67%). 1H NMR (DMSO-d6, 400 MHz)  9.11 (s, 2H); 3.86, (t, 4H, J=6.1 Hz); 1.74 (m, 4H); 
1.52 (m, 4H). MS [M+1]=223.2 
 
1-(5-nitropyrazin-2-yl)azepane (45e) 
Prepared from 0.2 g (1.2 mmol) 2-chloro-5-nitro-pyrazine analogous to (10) yielding 0.244 g 
(87%). 1H NMR (DMSO-d6, 400 MHz)  9.03 (d, 1H, J=1 Hz); 8.12 (d, 1H, J=1.3 Hz); 3.82 (br 
d, 4H, J=18 Hz); 1.76 (br s, 4H); 1.50 (m, 4H). MS [M+1]=223.2 
 
1-(2-fluoro-4-nitro-phenyl)azepane (45f) 
Prepared from 0.2 g (1.2 mmol)  3,4-difluronitrobenzene analogous to (10) yielding 0.236 g 
(78%). 1H NMR (DMSO-d6, 400 MHz)  7.92 (d, 2H, J=13.4 Hz); 6.98 (t, 1H, J=9.3 Hz); 3.59 (t, 





Prepared from 0.2 g (1.2 mmol) 2,4-difluoro-1-nitrobenzene analogous to (10) yielding 0.252 g 
(84%). 1H NMR (DMSO-d6, 400 MHz)  7.82 (dd, 1H, J=6.3, 9.1 Hz); 6.96 (dd, 1H, J=2.5, 12.6 
Hz); 6.64 (m, 1H); 3.23 (t, 4H, J=5.5 Hz); 1.73 (br s, 4H); 1.50 (m, 4H). MS [M+1]=239.2 
 
N-[6-(azepan-1-yl)-3-pyridyl]-2-(1-piperidyl)acetamide (46) 
Prepared from (45a) via Scheme 2 and analogous to General Procedure A yielding 0.007 g 
(14%). 1H NMR (DMSO-d6, 400 MHz)  10.83 (s, 1H); 8.35 (br d, 1H J=2.5 Hz); 7.86 (dd, 1H, 
J=2.2, 9.6 Hz); 7.10 (br d, 1H, J=8.9 Hz);4.11 (s, 2H); 3.65 (t, 4H, J=5.9 Hz); 3.48 (m, 2H); 3.05 
(br s, 2H); 1.78 (m, 10 H); 1.50 (m, 4H). MS [M+1]=317.2 
 
N-[5-(azepan-1-yl)-2-pyridyl]-2-(1-piperidyl)acetamide (47) 
Prepared from (45b) via Scheme 2 and analogous to General Procedure A yielding 0.045 g 
(93%). 1H NMR (DMSO-d6, 400 MHz)  10.75 (s, 1H); 7.84 (m, 2H); 7.18 (dd, 1H, J=3.4, 9.1 
Hz) 4.08 (d, 2H, J=5.6 Hz) 3.47 (m, 6H); 3.01 (m, 2H); 1.77 (m, 10H); 1.45-1.29 (4H). MS 
[M+1]=317.3 
 
tert-butyl N-[6-(azepan-1-yl)pyridazin-3-yl]carbamate (48) 
 To 0.20 g of 45c, 0.92 g cesium carbonate, 0.22 g tert-butyl carbamates, and 0.074 g Brettphos 
precat G1241  was added 4.7 mL deoxygenated 1,4-dioxane. The mixture was stirred and heated to 
110 ⁰C for 24 hours and then diluted with CH2Cl2, washed with 1N aqueous HCl and brine, dried 
over MgSO4, filtered, and concentrated before carried over to next step.  
110 
 
    
6-(azepan-1-yl)pyridazin-3-amine (49) 
 To a stirring room temperature solution of 0.1 g (0.342 mmol) (48) crude in 4 mL CH2CL2 was 
added 1 mL trifluoroacetic acid. The reaction mixture was stirred for 8 hours and then diluted 
with CH2Cl2, washed with saturated sodium bicarbonate and brine, dried over MgSO4, filtered 
and concentrated. Purification by flash chromatography (Biotage Isolera One, 24g silica gel, 
linear gradient 1%-20% MeOH:CH2Cl2) afforded 0.05 g of (49) (76%). 1H NMR (DMSO-d6, 400 
MHz)  7.05 (d, 1H, J=9.6 Hz); 6.80 (d, 1H, J= 9.9 Hz); 5.72 (br s, 2H) 3.54 (t, 4H, J=5.1 Hz); 
1.67 (m, 4H); 1.45 (M, 4H). MS [M+1]=193.2 
 
N-[6-(azepan-1-yl)pyridazin-3-yl]-2-(1-piperidyl)acetamide (50) 
 Prepared from (49) via Scheme 2 and analogous to General Procedure A yielding 0.012 g 
(24%). 1H NMR (DMSO-d6, 400 MHz)  9.80 (br s, 1H) 8.12 (d, 1H, J=10.1 Hz); 7.60 (d, 1H, J= 
9.3 Hz); 4.18 (s, 2H); 3.70 (t, 4H, J=5.8 Hz); 3.49 (m, 2H); 3.05 (m, 2H); 1.78-1.69 (m, 8H); 
1.51-1.43 (M, 6H).  MS [M+1]=318.2 
 
N-[2-(azepan-1-yl)pyrimidin-5-yl]-2-(1-piperidyl)acetamide (51) 
Prepared from (45d) via Scheme 2 and analogous to General Procedure A yielding  0.044 g 
(91%). 1H NMR (DMSO-d6, 400 MHz)  10.44 (s, 1H); 8.48 (s, 2H); 4.08 (d, 2H, J=4.8); 3.71 (t, 
4H, J=5.9); 3.48 (m, 2H); 3.02 (m, 2H); 1.78 (m, 10H); 1.49 (m, 4H). MS [M+1]=318.2 
 
N-[5-(azepan-1-yl)pyrazin-2-yl]-2-(1-piperidyl)acetamide (52) 
Prepared from (45e) via Scheme 2 and analogous to General Procedure A yielding  0.043 g 
(90%). 1H NMR (DMSO-d6, 400 MHz)  10.67 (s, 1H); 8.71 (m, 1H); 7.92 (m, 1H); 4.11 (d, 2H, 






Prepared from (45f) via Scheme 2 and analogous to General Procedure A yielding  0.041 g 
(87%). 1H NMR (DMSO-d6, 400 MHz)  10.48 (s, 1H); 7.46 (dd, 1H, J=2.6, 16 Hz); 7.14 (dd, 
1H, J=2.5,8.8 Hz); 6.93 (m, 1H); 4.05 (d, 2H, J=4.8 Hz); 3.47 (m, 2H); 3.30 (t, 4H, J= 5.7); 3.02 
(m, 2H); 1.77 (m, 10H); 1.55 (m, 4H). MS [M+1]=334.2 
 
N-[4-(azepan-1-yl)-2-fluoro-phenyl]-2-(1-piperidyl)acetamide (54) 
Prepared from (45g) via Scheme 2 and analogous to General Procedure A yielding  0.042 g 
(89%). 1H NMR (DMSO-d6, 400 MHz)  9.73 (s, 1H); 7.39 (dd, 1H, J=6.2, 8.5 Hz); 6.90 (dd, 1H, 
J=2.7, 11.6 Hz); 6.76 (td, 1H, J=2.8, 7.9 Hz); 4.12 (s, 2H); 3.48 (d, 2H, J=11.4 Hz); 3.12-3.04 (m, 
6H); 1.78-1.62 (14H) MS [M+1]=334.2 
 
2-(8-azabicyclo[3.2.1]octan-8-yl)-N-[6-(azepan-1-yl)-3-pyridyl]acetamide (55) 
 Prepared from (45a) via Scheme 2 and analogous to General Procedure A yielding 0.042 g 
(81%). 1H NMR (DMSO-d6, 400 MHz)  10.74 (s, 1H); 8.34 (d, 1H, J=2.3 Hz); 7.86 (m, 1H); 
7.04 (m, 1H); 4.00 (m, 4H); 3.65 (t, 4H, J=5.9 Hz); 2.17 (m, 2H); 2.04 (m, 1H); 1.94 (m, 2H); 
1.74 (m, 5H); 1.66 (m, 4H); 1.54 (m, 4H). MS [M+1]=343.2 
 
FluxOr Assay 
 See Chapter II materials and methods. 
Electrophysiology 





Test compounds were incubated at a concentration of 1 and 10 µM with 0.5mg/ml pooled mixed 
gender human live microsomes (Xenotech, LLC) in incubation buffer (10mM Magnesium 
Chloride, 0.1M Potassium Phosphate, pH 7.4) in a 37°C water bath.  After a 5 minute pre-
incubation, reactions were initiated by addition of cofactors, β-NADPH (nicotinamide adenine 
dinucleotide phosphate) and UDPGA (uridine diphosphate gluronic acid, at a final concentration 
1mM and 2mM, respectively.  Reactions were terminated at five separate time points (0, 10, 20, 
30 and 60min) by addition of three volumes of ice-cold 0.1% formic acid in acetonitrile.  After 
mixing by vortex, the quenched reactions were centrifuged at 2650g for 30 minutes.  The 
supernatants were then transferred and diluted with an equal volume of 0.1% formic acid in water.  
5µL  of each sample was injected and analyzed by LC/MS.  The percent remaining at each time 
point was determined by comparing the internal standard response ratio to that at time 0 minute.  
The half-life and the intrinsic clearance were determined using Michaelis-Menton non-linear 
regression analysis. The samples were analyzed using an Agilent 6540 QTOF with Jet Stream 
Electrospray Ionization Source (ESI) and Agilent 1290 UHPLC.  Solvents were 0.1% formic acid 
in water (A) and 0.1% formic acid in acetonitrile (B).  Chromatographic separation was achieved 
over 2.5 minute using a Waters Acquity UPLC BEH C18 2.1 x 50mm, 1.7micron with a binary 
gradient starting at 5% B for 0.2minutes.  The percent B was then increased to 95% from 0.2 to 
1.2 minute. The gradient returned to initial conditions immediately at 1.2 minutes. The mass spec 
acquisition was performed using full scan MS from m/z 100 to 500 with the following source 
conditions: Drying and Sheath Gas temperatures at 350°C and flows at 11L/min; Nebulizer- 
30psig, VCap, Nozzle and Fragmenter voltages at 3000V, 600V and 125V, respectively. 
 
Rat pharmacokinetics 
 Male Sprague Dawley rats were catheterized using the Instech Pinport system through jugular 
vein.  Rats were fasted for 16 hours prior to dosing with ad libitum access to water.  Three rats 
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were dosed 1mg/kg IV by tail vein injection and three rats were dosed 10mg/kg PO with a 
1mg/mL solution of LI-967 in a solution of 0.5% 0.1M citric acid in water. 200µL of blood was 
collected in lithium heparin treated tubes at 5, 15, and 30minutes and at 1, 4, 8, and 24 hours via 
jugular vein catheter.  The port was flushed with 20unit/mL lithium heparin in 50% 
water/glycerol solution (1:1, v/v).  The blood was centrifuged at at 3200rpm for 12 minutes to 
collect plasma. Plasma was then collected into Thermoscientific Matrix tubes and stored at -80C 
until analysis. 
 
Mouse blood-brain barrier penetration  
 Male C57BL/6J mice, 5 mice/timepoint, were injected IP with a 1mg/mL solution of LI-967 in a 
solution of 0.5% 0.1M citric acid in water.  At 0.5, 1, 2 and 8 hours the mice were anaesthetized 
with isoflurane and the blood was drawn via cardiac puncture in the open chest cavity and 
collected in lithium heparin treated tubes.  The brain was perfused with phosphate buffered saline 
(PBS) and harvested.  The blood was centrifuged at 3200rpm for 12 minutes to separate the 
plasma. Plasma was then collected in matrix tubes and stored with the intact brains in -80C 
freezer until analysis.  The brains lysed in a 2x volume of PBS, pH 7.4 adjusted with 1M HCl 
resulting in a 3x homogenate (w/w). 
 
Analysis of Rat PK and Mouse BBB 
 The samples were extracted with a 3x volume (v/v) of 0.1% formic acid in acetonitrile with 
1mg/mL LI-664 (internal standard) and centrifuged at 2650 rcf for 30minutes.  The supernatant 
was mixed with 0.1% formic acid in water and analyzed using an Agilent 6540 QTOF with Jet 
Stream Electrospray Ionization Source (ESI) and Agilent 1290 UHPLC.  Solvents were 0.1% 
formic acid in water (A) and 0.1% formic acid in methanol (B).  Chromatographic separation was 
achieved over 2.5 minute using a Waters Acquity UPLC BEH C18 2.1 x 50mm, 1.7micron, 
column with a binary gradient starting 5% B.  The gradient continued with B increasing to 95% 
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from 0 to 1.2 minutes with immediate drop to initial conditions at 1.21minutes.  The mass spec 
acquisition was performed using full scan MS from m/z 100 to 1000 with the following source 
conditions: Drying and Sheath Gas temperatures at 350°C and flows at 11L/min; Nebulizer- 
30psig, VCap, Nozzle and Fragmenter voltages at 3000V, 600V and 125V, respectively. 
Data Analysis 
 cLogD (pH 7.4), TPSA, and pKa calculated by ACD Labs Percepta. IC50 values calculated from 





















Conclusion and Perspective 
 
 In this work, we have established the infrastructure necessary for Kv11.1-3.1 drug discovery 
while simultaneously revealing new findings concerning Kv11.1-3.1 molecular biology and anti-
psychotic action. In the first chapter, we characterized the expression, trafficking, and activity 
deficiencies of Kv11.1-3.1. These findings lead to the development of a biochemical assay screen 
for pharmacological trafficking rescue which resulted in the observation that proteasome 
inhibition drastically rescued these deficits. Using this tool, we were able to create robust high-
throughput assays, allowing us to screen molecules and proceed with the development pipeline. 
By focusing on maximizing expression while limiting endogenous degradation, we were able to 
adapt Kv11.1-3.1 onto Kv11.1-1A IonWorks Quattro™ platforms for high-throughput 
electrophysiology for a secondary assay. A small panel of antipsychotics was used to evaluate the 
accuracy of this platform. While not congruent with literature reports of manual voltage-clamp 
data from various cells lines for certain compounds, this assay was a seemingly better predictor of 
compound selectivity compared to the FluxOR assay and is a useful tool for validating that aspect. 
Using both of these assays, along with manual voltage-clamp in HEK 293 cells, we found 
clozapine to preferentially inhibit Kv11.1-3.1. Finally, we used the FluxOR assay to drive 
medicinal chemistry studies of a hit found in collaboration with the NCGC/NCATS. SAR of the 
hit led to the synthesis of compound 55 (Chapter III) which boasts 100-fold Kv11.1-3.1/Kv11.1-
1A selectivity at mid-nanomolar potency. While this compounds displays an incredible 16:1 
mouse brain to plasma ratio, it is cleared almost instantaneously in rats. Regardless, this 
compound has the potential for further modification to alleviate these metabolic issues and be 
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used as a tool compound in rodent behavioral assays.  
 Of specific interest in modifying 55 is further modification to the azepane ring portion of the 
molecule, combination of the 3.2.1 azabicyclo terminal group with the fluorinated cores, and 
SAR from trimming back the various rings. Modifications to the azepane core are especially 
desired as few existing analogs have increased the basicity of the contained nitrogen and bicyclo 
analogs have yet to be tested. In order to improve metabolic stability, metabolic ID studies will be 
used to guide the synthesis of additional analogs that will either remove the reactive hotspots 
identified or add substituents to lessen the degree of metabolic enzyme action. Once these new 
compounds are tested in vitro using microsomes, they will be evaluated in the same mouse blood-
brain barrier and rat PK assays. Data from these studies will be used to guide dosing and timing 
for t-maze and novel object location cognitive tests in rodents. If any of these compounds are 
successful, more strenuous cardiotoxicity testing will need to be done in Kv11.1-1A binding 
assays, additional electrophysiology, and in vivo studies using guinea pigs prior to larger animals 
(such as dogs).242 If a putative compound is able to pass these major hurdles, it may be 
appropriate to initiate investigational new drug (IND)-enabling studies in order to complete the 
preliminary steps prior to first-in-man phase 1 clinical trials.  
 However, the usefulness of such a compound in the treatment of schizophrenia is still unclear. 
While an aim of the same genetic studies that discovered Kv11.1-3.1 was to find novel drug 
targets, the evidence in the literature still traces Kv11.1-3.1 to dopamine action.189 Granted, this is 
likely a biased model due to natural proclivity towards what is already known, but without 
knowledge of an exact contribution or effect, it is difficult to estimate the likelihood that a 
potential drug would attract the necessary resources for commercialization and clinical access. 
Studies examining the differential response of clozapine and risperidone in the risk SNP patient 
population may provide some statistical evidence that Kv11.1-3.1 does contribute to the disease 
pathology, perhaps mandating a new compound with clozapine-like pharmacology and an 
emphasis on Kv11.1-3.1 blockade. In order to determine the contribution of Kv11.1-3-1 
117 
 
overexpression in schizophrenia, it may be of use to examine neuronal firing in more humanized 
systems, such as stem cells or brain organoids.243 
 What may be a potentially faster route to relevance is in the continued examination of KCNH2 
risk SNPs in the context of other schizophrenia-associated genes. KCNH2 is not among the 
significant loci reported in any iteration of the PGC consortium studies, yet we have strong 
evidence that it is indeed associated with schizophrenia in certain contexts. One possible reason 
for this disconnect is the limitations of the PGC GWAS studies to detect epistatic effects and the 
possible strong regulation of Kv11.1-3.1 expression by ERAD and the proteasome. As mentioned 
previously in Chapter II, the ubiquitin-proteasome system (UPS) and ERAD proteins have been 
implicated in schizophrenia, especially via downregulation. While these reports attempt to model 
deficient UPS to increased lysosome activity which targets neurotransmitter receptors, myelin, 
BDNF, etc., Kv11.1-3.1 presents a straightforward exacerbation of risk.218,219,244 In addition to 
these highly contextual studies, a 20S subunit member PSMA4 has been recently found to be 
significantly associated with schizophrenia in the PGC GWAS which may be a powerful tool for 
KCNH2 epistatic computational studies, or as a member of a general “UPS score” that would 
recapitulate total UPS activity. It has also been recently discovered in our lab that AS3MT, a top 
PGC GWAS hit, interacts with multiple members of the UPS and thus may be another “effector” 
in a conjectured “UPS-mediated schizophrenia” subtype.90 The global down-regulation of UPS-
effector relationship in this hypothesis also resists the plague of cellular mosacism to a certain 
extent, as a variety of targets play highly exchangeable or interactive roles in UPS and the degree 
to which proteins can assume effector roles is seemingly limitless. Clearly this is difficult to 
approach for the purpose of designing new therapeutics beyond gene-editing, although Kv11.1-
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